Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Human

Subclass of:

435 - Chemistry: molecular biology and microbiology

435325000 - ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE

435363000 - Primate cell, per se

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
435372000 Blood, lymphatic, or bone marrow origin or derivative 64
435368000 Nervous system origin or derivative 20
435370000 Hepatic origin or derivative 17
435369000 Renal origin or derivative 16
435371000 Epithelial origin or derivative 13
435367000 HeLa cell or derivative 5
20130164840Semi-Stable Production of Lentiviral Vectors - The present invention provides a new semi-stable packaging cell line and a method to produce lentiviral vectors (LV), using the semi-stable packaging cell line. New methods and packaging cell lines of the invention are generated using a baculo-AAV hybrid system for stable expression of structural and regulatory lentiviral proteins, such system comprising a baculoviral backbone containing an integration cassette flanked by AAV ITRs, in combination with a plasmid encoding rep protein. This system allows to obtain a stable integration of the structural and regulatory HIV-1 proteins gag/pol and rev. The system allows to obtain a cell line including the structural and regulatory HIV proteins gag/pol and rev, to be used for a semi-stable LV production.06-27-2013
20120115227GENE TRANSFER VECTORS COMPRISING GENETIC INSULATOR ELEMENTS AND METHODS TO IDENTIFY GENETIC INSULATOR ELEMENTS - The present invention relates to a gene transfer vector (GTV) and in particular to an integrating gene transfer vector (IGTV), which comprises at least one genetic insulator element (GIE), wherein the each comprises at least two copies of an element selected from the group consisting of: a CTF binding site; a first CTCF binding site and a second CTCF binding site, wherein the first and the second CTCF binding sites are derived from the regulatory sequences of different genes.05-10-2012
20090155901Mammalian Cell Line Expressing Inducible c-Src - The present invention is directed to a unique mammalian cell line expressing inducible c-Src, and, particularly, a unique human cell line overexpressing c-Src in an inducible manner.06-18-2009
20100227400MONOMERIC AND DIMERIC FLUORESCENT PROTEIN VARIANTS AND METHODS FOR MAKING SAME - The present invention relates generally to fluorescent proteins and fluorescent protein variants, and more specifically to monomeric and dimeric forms of Anthozoan fluorescent proteins. In one aspect, the present invention provides variants of fluorescent proteins, where the variants have a reduced propensity to tetramerize, and form dimeric or monomeric structures. In a further aspect, the present invention provides variants of fluorescent proteins, the variants being characterized by more efficient maturation than corresponding fluorescent proteins from which they are derived. The invention also relates to methods of making and using such fluorescent proteins and fluorescent protein variants, including fluorescent protein monomers and dimers.09-09-2010
20090170194TEAL FLUORESCENT PROTEINS - An isolated nucleic acid sequence encoding a non-oligomerizing Clavularia teal fluorescent protein (TFP) variant having a tyrosine-derived chromophore, and fragments and derivatives thereof. Also provided is a method for engineering the nucleic acid sequence, a vector comprising the nucleic acid sequence, a host cell comprising the vector, and use of the vector in a method for expressing the nucleic acid sequence. The present invention further provides an isolated nucleic acid, or mimetic or complement thereof, that hybridizes under stringent conditions to the nucleic acid sequence. Additionally, the present invention provides a non-oligomerizing TFP variant encoded by the nucleic acid sequence, as well as derivatives, fragments, and homologues thereof. Also provided is an antibody that specifically binds to the TFP variant. The present invention further provides a tandem dimer comprising two TFP dimers, operatively linked by a peptide linker.07-02-2009
Entries
DocumentTitleDate
20090311782METHOD FOR PROMOTING DIFFERENTIATION OF STEM CELL INTO INSULIN PRODUCING CELL - A method for promoting a differentiation of stem cells into insulin producing cells is provided. The method includes steps of suspending the stem cells in a first culture medium, aggregating the stem cells to form a cell pellet, and culturing the cell pellet in a second culture medium to promote the differentiation of the stem cells of the cell pellet into the insulin producing cells.12-17-2009
20110183414Expansion Medium for CD34-Negative Stem Cells - This invention provides a cell growth medium comprising (a) a human platelet lysate free of solid matter greater than 0.22 μm in diameter, wherein the lysate constitutes from 2% to 15% of the total volume of the cell growth medium; (b) a human fresh frozen plasma (FFP) filtrate free of solid matter greater than 0.22 μm in diameter, wherein the FFP filtrate constitutes from 1% to 10% of the total volume of the cell growth medium; (c) heparin at a concentration of from 0 U/ml to 10 U/ml of the cell growth medium; (d) L-glutamine at a concentration of from 0.5 mM to 10 mM; and (e) a serum-free, low glucose medium suitable for mammalian cell growth, wherein the serum-free, low glucose medium constitutes from 75% to 97% of the total volume of the cell growth medium, and may contain the L-glutamine of part (d); wherein the cell growth medium permits the expansion of human CD3407-28-2011
20090305404Methods and compositions relating to blastomere-derived human embryonic stem cells - The invention provides methods for producing human embryonic stem cells from blastomeres with reduced or no animal cells or products, including no serum regardless of source and including xeno-free conditions, without compromising derivation efficiency.12-10-2009
20090142830Aqueous Solution for Cell Preservation - To provide an aqueous solution for cell preservation which is free of a natural animal-derived component such as a basal medium or serum. An aqueous preservation solution showing a high cell survival rate was obtained by removing a natural animal-derived component such as a basal medium or serum and controlling other components and their concentrations.06-04-2009
20100009442Stem Cell Culture Medium and Method - Stem cells such as embryonic stem cells (ES cells), including human ES cells, are cultured in a medium comprising a ROCK inhibitor, and a stem cell culture medium, optionally serum free, comprises a ROCK inhibitor.01-14-2010
20120184032Method of In Vitro Differentiation of Neural Stem Cells, Motor Neurons and Dopamine Neurons From Primate Embryonic Stem Cells - A method of differentiating embryonic stem cells into ventral spinal progenitor cells is disclosed. In one embodiment, the invention comprises culturing a population of cells comprising a majority of cells that are characterized by an early rosette morphology and are Sox107-19-2012
20120184031ANTISENSE INHIBITION VIA RNASE H-INDEPENDENT REDUCTION IN MRNA - The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.07-19-2012
20110195497METHOD FOR PURIFYING MESENCHYMAL STEM CELLS - The invention relates to a method for purifying mesenchymal stem cells, producing cells corresponding to prior art, the cells obtained being characterised by an increased proliferation capacity while maintaining the multipotency and typical antigen characteristics. To this end, mesenchymal stem cells that can be multiplied in a significantly improved manner compared to prior art are first provided and can also be differentiated, after a longer cultivation period, in three mesenchymal directions.08-11-2011
20100047906GERM LINEAGE DERIVED FEEDER CELLS AND METHODS THEREOF - The present disclosure relates to human germ layer derived feeder cells (GLDF cells) and method of generation thereof. Further, it relates to a method for culturing and propagating human embryonic stem cells (hESCs) in a substantially undifferentiated state for several passages on the human GLDF cells. In particular, the present disclosure relates to human GLDF cells which are capable of supporting proliferation of hESCs in a substantially undifferentiated and pluripotent state for several passages.02-25-2010
20100112687NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOF - The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more ERBB family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more ERBB family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more ERBB family gene in a cell or in a subject to treat one or more ERBB family-related disease.05-06-2010
20100075417Methods and devices for isolating embryonic stem cells - Methods, devices and kits are provided for isolating or enriching multicellular embryonic stem (ES) cell colonies from a mixture of multicellular ES cell colonies and single ES cells present in a cellular suspension, by utilizing a filtration matrix that selectively excludes passage of multicellular ES cell colonies. Isolated or enriched multicellular ES cell colonies can be used for propagating pluripotent ES cells.03-25-2010
20100075416Growth Factor Supplement for Stem Cell Cultures - Disclosed is a growth factor supplement for stem cell culture media, stem cell culture media supplemented with the growth factor supplement, and methods for growing and maintaining stem cells in culture. The invention particularly relates to human stem cells, more particularly human embryonic stem cells, neonatal stem cells, adult stem cells, and IPS cells.03-25-2010
20120244616METHOD OF OOCYTE CRYOPRESERVATION USING ANTIFREEZE PROTEIN - Disclosed is a method for cryopreserving an oocyte by adding an antifreeze protein to a cryopreservation liquid (equilibrium solution, vitrification solution). The disclosed cryopreservation method of an oocyte minimizes damage to the oocyte, which increases the survival rate of the oocyte after freezing and thawing of the oocyte, and improves a fertilization rate, and a blastocyst development ratio of the oocyte.09-27-2012
20130078720METHOD FOR INDUCING PLURIPOTENCY IN HUMAN SOMATIC CELLS WITH PRDM14 OR NFRKB - Methods of inducing pluripotency in human somatic cells and methods of maintaining pluripotency in human embryonic stem cells (hESCs) are provided, as well as cells and uses of employing such cells. The methods comprise culturing cells in the presence of (i) OCT4 and SOX2; (ii) at least one of KLF4 and c-MYC; and at least one of PRDM14 and NFRKB.03-28-2013
20130078719NOVEL SHRNA MOLECULES AND METHODS OF USE THEREOF - The present invention relates to certain novel shRNA molecules and methods of use thereof. According to certain embodiments of the present invention, methods for reducing the expression level of a target gene are provided. Such methods generally comprise providing a cell with one or more precursor nucleic acid sequences that encode two or more RNA molecules. A first RNA molecule comprises a double stranded sequence, which includes a guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene. In addition, a second RNA molecule comprises a second double stranded sequence, which includes a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene. Preferably, the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene.03-28-2013
20130040387METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO SKELETAL MUSCLE OR SKELETAL MUSCLE PROGENITOR CELLS - A method for inducing the differentiation of pluripotent stem cells into skeletal muscle or skeletal muscle progenitor cells is provided. Specifically, a method for producing artificial skeletal muscle or skeletal muscle progenitor cells from human pluripotent stem cells is provided, comprising the following steps of: (1) culturing human pluripotent stem cells by suspension culture; (2) culturing a cell population after suspension culture by adhesion culture; (3) dissociating cells after adhesion culture; and (4) culturing the dissociated cells by adhesion culture. Artificial skeletal muscle or induced skeletal muscle progenitor cells prepared by the method are also provided.02-14-2013
20120208274ADIPOSE-DERIVED STEM CELLS AND LATTICES - The present invention provides adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF) and adipose-derived lattices, alone and combined with the ADSCs of the invention. In one aspect, the present invention provides an ADSC substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The ADSCs can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the ADSCs can be expanded and cultured to produce molecules such as hormones, and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a adipose-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.08-16-2012
20090275128MEDIUM AND CULTURE OF EMBRYONIC STEM CELLS - Previous methods for culturing human embryonic stem cells have required either fibroblast feeder cells or a medium which has been exposed to fibroblast feeder cells in order to maintain the stem cells in an undifferentiated state. It has now been found that if high levels of fibroblast growth factor, gamma amino butyric acid, pipecholic acid, lithium and transforming growth factor beta are added to the medium in which the stem cells are cultured, the stem cells will remain undifferentiated indefinitely through multiple passages, even without feeder cells or conditioned medium.11-05-2009
20100099185METHOD OF MAKING BIOLOGICALLY ACTIVE ALPHA-BETA PEPTIDES - Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising α-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the α-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with β-amino acid residues, and the α-amino acid residues are distributed in a repeating pattern.04-22-2010
20120264209METHODS AND DEVICES FOR DIFFERENTIATING PLURIPOTENT STEM CELLS INTO CELLS OF THE PANCREATIC LINEAGE - Methods and devices for culturing human pluripotent stem cells to produce cells of the pancreatic lineage are disclosed. The methods include steps of culturing the stem cells under conditions that induce the expression of mesendoderm/primitive streak and definitive endoderm markers in a chemically defined medium including an effective amount of i) fibroblast growth factor, ii) Activin A, and iii) bone morphogenetic protein. The methods further include the steps of culturing cells under conditions favoring the formation of at least one of intact embryoid bodies and pancreatic progenitor PDX110-18-2012
20100323439MICROFLUIDIC CELL CULTURE DEVICE - Microfluidic devices for cell culturing and methods for using the same are disclosed. One device includes a substrate and membrane. The substrate includes a reservoir in fluid communication with a passage. A bio-compatible fluid may be added to the reservoir and passage. The reservoir is configured to receive and retain at least a portion of a cell mass. The membrane acts as a barrier to evaporation of the bio-compatible fluid from the passage. A cover fluid may be added to cover the bio-compatible fluid to prevent evaporation of the bio-compatible fluid.12-23-2010
20130210139PROTEOLIPIDBEADS AND METHOD OF USE THEREOF - The subject matter disclosed in this specification pertains to the transfer of compounds of interest into a target biological cell. Specifically, discrete particles that are surrounded in three dimensions with phospholipid bilayers are provided wherein the compound of interest (e.g.) a protein are free to laterally move within the bilayer. The particles may be embedded within a hydrogel matrix. In some embodiments, stem cells are co-cultured in the hydrogel matrix to facilitate the absorption of the compound of interest.08-15-2013
20090155900CELL CULTURE MATRICES - The present invention relates to cell culture, more specifically to cell culture which may be cell culture such as stem cell culture, embryonic stem cell (ESC) culture and primary cell culture. Disclosed herein are compositions of matter, including without limitation cell matrices, matrix-forming formulations and cell cultures, wherein the cells may be cells such as stem cells, such as ESC, or primary cells, such as keratinocyte and fibroblast cells. Also disclosed herein are articles of manufacture comprising one or more of the compositions of matter of the invention, methods of making and using the compositions of matter and articles of manufacture of the invention, business methods, and tangible media comprising instructions or plans for one or more of the methods and compositions of the invention.06-18-2009
20100105134NUCLEIC ACID COMPOUNDS FOR INHIBITING GENE EXPRESSION AND USES THEREOF - The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), and blunt ended double-stranded ribonucleic acid molecules capable of decreasing or silencing expression of a target gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target mRNA. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease or condition associated with the target gene.04-29-2010
20100105133Somatic Cells for Use in Cell Therapy - The present invention generally concerns cell therapy and products for use in such therapy. Particularly, the invention provides a preserved cell preparation essentially free of one or more members of a group of cryoprotecting agents consisting of polyalcohols, DMSO and cryoprotecting proteins, the preserved cell preparation comprising somatic cells and at least one polyphenol, wherein upon reconstitution of cells in the cell preparation, at least a portion of said stem cells are viable, said portion being sufficient for use of the cell preparation in stem cell therapy. The invention also provides cells reconstituted from preserved somatic cells, and the use of the reconstituted cells in cell therapy. A preferred cell preparation in accordance with the invention comprises stem cells, preferably human stem cells.04-29-2010
20100041140NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF - The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing BCL2 gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-over-lapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a BCL2 mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a BCL2 gene in a cell or in a subject to treat a BCL2-related disease.02-18-2010
20080213887METHODS AND COMPOSITIONS FOR CRYOPRESERVING OOCYTES - Disclosed are methods and compositions useful for cryopreserving oocytes and, in particular, mammalian oocytes such as human oocytes.09-04-2008
20090298169Pancreatic and Liver Endoderm Cells and Tissue by Differentiation of Definitive Endoderm Cells Obtained from Human Embryonic Stems - The invention relates to methods that allow for the efficient differentiation to form pancreatic endoderm cells from pluripotent stem cells such as human embryonic stem cells and definitive endoderm cells. The invention is directly applicable to the ultimate generation of pancreatic beta cells that could be used as part of a therapy to treat or even cure diabetes. Additionally, the present invention may be used to generate liver endoderm cells from human embryonic stem cells and definite endoderm cells as well. This invention relates to a method for generating definitive endoderm and pancreatic endoderm cells from stem cells, preferably human embryonic stem cells using defined media in the absence of feeder cells. A simply two step procedure to provide pancreatic endoderm cells from embryonic stem cells represents further embodiments of the present invention.12-03-2009
20130029416DIFFERENTIATING INDUCED PLURIPOTENT STEM CELLS INTO GLUCOSE-RESPONSIVE, INSULIN-SECRETING PROGENY - This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided.01-31-2013
20130029417Suppressors of RNA Silencing as Modulators of miRNA Levels - The invention describes use of RNA silencing suppressors or interactors of the suppressors to bring the expression of microRNAs involved in any disease, including malignant neoplasia, back to its normal level. More specifically the present invention provides a method to regulate many miRNAs at the same time. Most of the suppressors according to this invention are coded by plant viruses that unexpectedly can affect RNA silencing and modulate miRNA expression levels in mammalian cells. Also suppressors of endogenous origin are described as able to modulate miRNA expression levels.01-31-2013
20130029415CELL CULTIVATION METHOD AND CELL CULTURE - Provided is a cell cultivation method in which the cell is cultured using a peptide hydrogel as a scaffold, for carrying out high-dimensional culture of a cell such as porcine hepatocyte, human hepatocyte, porcine pancreatic islet or human pancreatic islet for a long period under conditions where cell survival, cell morphology and cell functions are maintained. Also provided are a cell culture including a cell and a peptide hydrogel obtained by the above-described cultivation method, a bioreactor including the cell culture, and a cell preparation including the cell culture.01-31-2013
20130029414CELL CULTURE MEDIA, KITS AND METHODS OF USE - Albumin-supplemented and xenogeneic product-free cell culture media, cell culture media supplements, and cell culture media kits for the support of primary culture of normal non-hematopoietic cells of mesodermal origin suitable for both research and clinical applications.01-31-2013
20120164729COMPOSITION FOR CULTURING PLURIPOTENT STEM CELLS AND USE THEREOF - A means for feeder-free culture which can sufficiently maintain the undifferentiation potency of pluripotent stem cells such as iPS cells even without using heterologously derived cells or proteins, is provided.06-28-2012
20090124007Method for the Simultaneous Primary-Isolation and Expansion of Endothelial Stem/Progenitor Cell and Mesenchymal Stem Cell Derived From Mammal Including Human Umbilical Cord - Disclosed herein is a method for isolating and culturing the endothelial stem/progenitor cells and mesenchymal stem cells derived from the umbilical cord of mammals, including human beings. More specifically, disclosed are a method for isolating and culturing endothelial stem/progenitor cells and mesenchymal stem cells at high purity from the umbilical cord of mammals, including human beings, and preferably from the human umbilical cord, as well as endothelial stem/progenitor cells and mesenchymal stem cells, isolated and cultured according to said method, and a method for freezing and thawing the isolated and cultured cells. According to the disclosed method, endothelial stem/progenitor cells and mesenchymal stem cells can be easily isolated and purified with high purity from umbilical cord, and can be cultured with high viability for a long period of time.05-14-2009
20090093053CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases - An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain capable of specifically binding a CD44 polypeptide as set forth in SEQ ID NO: 2 and incapable of binding a CD44 polypeptide selected from the group consisting of: SEQ ID NO: 4 or 6.04-09-2009
20090053804METHODS OF REDUCING INTRACELLULAR FATS FROM MAMMALIAN CELLS - The present invention provides methods of reducing or clearing fat from mammalian cells. The method comprises culturing the cells in an environment that facilitates: 1) reduction of de novo fatty acid synthesis, 2) activation or synthesis of fatty acid oxidizing enzymes, and/or 3) export of lipids out of the cells. Cells substantially free of fatty acid are also provided in this invention.02-26-2009
20090042287PDX1 EXPRESSING ENDODERM - Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.02-12-2009
20090305405USE OF TGF BETA SUPERFAMILY ANTAGONISTS AND NEUROTROPHINS TO MAKE NEURONS FROM EMBRYONIC STEM CELLS - This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.12-10-2009
20130071926COMPOSITIONS AND METHODS FOR GROWING HUMAN EMBRYONIC CELLS - Methods for deriving and cultivating human embryonic stem (ES) cells and maintaining their pluripotency in culture is provided by utilizing secreted products obtained from the culture medium of human embryonic germ (EG) cell derivatives, such as embryoid body-derived cells. Substrates include compounds such as collagen I, fibronectin, or superfibronectin, or extracellular matrix, typically human derived.03-21-2013
20130071925CELL CULTURE MEDIUM - The present invention relates to a cell culture medium for culturing human cells comprising an anti-coagulated total blood material wherein the hemoglobin level is from about 8 to about 16 g/dl. More particularly, the invention provides a cell culture medium in which cells present in the blood are disrupted and the insoluble remnants of the lysated cells are removed. Further, the invention provides a method for the preparation of a cell culture medium for culturing human cells, according to the invention.03-21-2013
20110039333DEFINED CONDITIONS FOR HUMAN EMBRYONIC STEM CELL CULTURE AND PASSAGE - The invention relates to human pluripotent cells. More specifically, the invention provides a chemically defined xeno-free culture system that allows for long term expansion of human pluripotent cells. This culture system allows for human pluripotent cell lines to be maintained in the pluripotent state for an extended time while maintaining a normal karyotype and the ability to differentiate into all three germ layers.02-17-2011
20130059376CULTURE VESSEL AND METHOD OF GROWING CELLS IN CULTURE VESSEL - A culture vessel and a method of growing cells in a culture vessel. The culture vessel includes a container and a plurality of agitators. The container receives a medium and cells. The plurality of agitators is positioned to contact the medium when received in the container and configured to promote suspension of the cells in the medium upon oscillation of the agitators. The agitators are at least one of coupled to and formed integrally with the container such that there is no relative movement there-between. The method includes receiving a medium and cells in a container and oscillating the medium such that the cells traverse along a longitudinal direction of the container.03-07-2013
20130059377STEM CELL DEFINED MEDIA FOR XENO-FREE AND FEEDER FREE CONDITIONS AND USES THEREOF - The invention provides a defined low protein culture medium for maintaining cells in an undifferentiated state, the medium comprising: a basal medium, an organic acid from the tricarboxylic acid cycle, nonessential amino acids, a combination of growth factors selected from the group consisting of FGF-2 protein, an IGF-1 protein or insulin, a Transferrin protein, and a TGF beta 1 protein, wherein the medium is essentially feeder-free, essentially xeno-free, essentially free of beta-mercaptoethanol, and essentially free of animal-derived or human-derived proteins.03-07-2013
20110014694USE OF ENTERIC GLIA - Methods of reducing tissue damage in the nervous system are disclosed. The methods involved administering enteric glial cells to an animal with a nerve injury. Methods of improving locomotor function in animal with a nerve injury are also disclosed.01-20-2011
20090269845PLURIPOTENT CELLS - The present invention is directed to pluripotent cells that can be readily expanded in culture on tissue culture substrate that is not pre-treated with protein or an extracellular matrix, and do not require a feeder cell line. The present invention also provides methods to derive the pluripotent cell line from human embryonic stem cells.10-29-2009
20110020929PARTIALLY ACTIVE MICROFLUIDIC SYSTEM FOR 3D CELL CULTIVATION AND METHOD FOR PERFUSION THEREOF - The invention relates to a partially active microfluidic system for cell cultivation comprising a multiwell system (01-27-2011
20110045588METHOD FOR CULTURING HUMAN PERIOSTEUM - The present invention provides a method for forcingly culturing a piece of human periosteum tissue in a shorter culture period, the method including the steps of: (1) placing a periosteum piece dissected from a patient on a culture dish containing no culture solution; (2) dropping platelet-rich plasma collected from the patient onto the surface of the periosteum piece on the culture dish and coagulating the platelet-rich plasma so as to cover the surface of the periosteum piece; (3) adding a first culture medium to the culture dish and growing the culture; and (4) growing the culture in a second culture medium containing a basic fibroblast growth factor and no platelet-rich plasma, after the step (3).02-24-2011
201201152263D CULTURING SYSTEMS FOR GROWTH AND DIFFERENTIATION OF HUMAN PLURIPOTENT STEM (hPS) CELLS - The present invention relates to the use of 3D culturing systems for the derivation of hepatocyte-like cells from human pluripotent stem cells (hPS). In particular, the invention concerns the directed differentiation and maturation of human pluripotent stem cells into hepatocyte like cells in 3D hollow fiber capillary bioreactors.05-10-2012
20120115225REPROGRAMMING OF SOMATIC CELLS WITH PURIFIED PROTEINS - Purified somatic cell reprogramming factors are described herein. The factors are particularly useful alone or in combination with at least one effector of cellular metabolism, in order to generate at least one reprogramming somatic cell. Methods for using at least one somatic cell reprogramming factor and at least one somatic cell reprogramming enhancing factor are pro-vided. Additionally, the cells generated from the methods are also described. The methods and cells may find use in personalized medicine applications.05-10-2012
20090239298Methods of generating embryoid bodies using three dimensional scaffolds - A method of generating embryoid bodies is provided. The method comprising culturing undifferentiated embryonic stem cells on a three dimensional scaffold under conditions suitable for formation of embryoid bodies, thereby generating the embryoid bodies.09-24-2009
20090011503Primate Embryonic Stem Cells - A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (−); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a particularly advantageous embodiment, the cells of the preparation are human embryonic stem cells, have normal karyotypes, and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed.01-08-2009
20090011502Pdx1 Expressing Endoderm - Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.01-08-2009
20120238015METHODS AND MATERIALS FOR INCREASING POTENCY OF CELLS - Disclosed herein are methods and materials for producing a more developmentally potent cell from a less developmentally potent cell. Specifically exemplified herein are methods that comprise introducing an expressible dedifferentiating polynucleotide sequence into a less developmentally potent cell, wherein the transfected less developmentally potent cell becomes a more developmentally potent cell capable of differentiating to a less developmentally potent cell of its lineage of origin or a different lineage.09-20-2012
20110027879Adipose-derived stem cells and lattices - The present invention provides adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF) and adipose-derived lattices, alone and combined with the ADSCs of the invention. In one aspect, the present invention provides an ADSC substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The ADSCs can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the ADSCs can be expanded and cultured to produce molecules such as hormones, and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a adipose-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.02-03-2011
20090275127VIABLE CELLS FROM FROZEN UMBILICAL CORD TISSUE - Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.11-05-2009
20100159588CONDITIONED MEDIA AND METHODS OF MAKING A CONDITIONED MEDIA - A stable and scalable process is provided to manufacture reduced serum umbilical cord tissue-derived (UTC)-conditioned media. The method includes the culture of a UTC under reduced serum conditions. Subsequently, the UTC is washed and grown in serum-free basal media. After approximately 24 hours, the conditioned media is collected, filtered and concentrated by use of an approximately 5 kDa or similar cut-off membrane.06-24-2010
20100068804METHODS OF STIMULATING EXPANSION OF HEMATOPOIETIC STEM CELLS - The present invention relates, in general, to hematopoietic stem cells (HSC) and, in particular, to methods of stimulating expansion of hematopoietic stem cells and to agents suitable for use in such methods.03-18-2010
20110129919Microcarriers for Stem Cell Culture - We disclose a particle comprising a matrix coated thereon and having a positive charge, the particle being of a size to allow aggregation of primate or human stem cells attached thereto. The particle may comprise a substantially elongate, cylindrical or rod shaped particle having a longest dimension of between 50 μm and 400 μm, such as about 200 μm. It may have a cross sectional dimension of between 20 μm and 30 μm. The particle may comprise a substantially compact or spherical shaped particle having a size of between about 20 μm and about 120 μm, for example about 65 μm. We also disclose a method of propagating primate or human stem cells, the method comprising: providing first and second primate or human stem cells attached to first and second respective particles, allowing the first primate or human stem cell to contact the second primate or human stem cell to form an aggregate of cells and culturing the aggregate to propagate the primate or human stem cells for at least one passage. A method of propagating human embryonic stem cells (hESCs) in long term suspension culture using microcarriers coated in Matrigel or hyaluronic acid is also disclosed. We also disclose a method for differentiating stem cells.06-02-2011
20130071927MEDIA AND METHODS FOR CELL CULTURE - The present invention provides a cell passaging medium comprising at least one agent capable of detaching from a surface a cell that is culture in vitro on said surface, and a water-soluble polymer capable of protecting the detached cell. The present invention also provides a cell culturing medium comprising one or more cell culture protectants capable of protecting cells in culture. The present invention further relates to the use of said media in methods for culturing cells in vitro or for deriving monolayer cell cultures of mammalian stem cells.03-21-2013
20100120142CULTURE OF HUMAN EMBRYONIC CELLS - The invention relates to a method for culturing human embryonic stem cells (hESCs) with a lectin. The invention relates also to the use of a lectin in a method for culturing human embryonic stem cells (hESCs) and a culture medium composition containing a lectin.05-13-2010
20090068734Human salivary gland-origin stem cell - A novel human stem cell which can be differentiated to cells constituting a plurality of human organs including human liver is disclosed. The human stem cell according to the present invention is originated from human salivary gland, which is CD49f-positive, and which can be differentiated to (1) a nestin-positive and albumin-positive cell, (2) an insulin-positive cell and (3) a glucagon-positive cell by culture in vitro.03-12-2009
20110300626Electrospun Ceramic-Polymer Composite As A Scaffold for Tissue Repair - The present invention relates to compositions and methods of preparing a three-dimensional matrix of micron sized electrospun fibers, wherein the electrospun fibers are formed from a electrospun composite comprising a bioactive ceramic component and a polymer component. The matrix provides an osteoconductive and osteoinductive scaffold supporting osteogenesis and thereby facilitates bone repair.12-08-2011
20110281350Tissue Processing System and Method - A tissue processing system includes a tray and a processing component. The processing component has teeth configured to dice, mince, and mix the tissue in the tray. In some versions, teeth of a rotary member mesh with teeth of a stationary member, such that the tissue is ground between the meshing teeth. The rotary member may be moved in an orbital path relative to the stationary member. In some versions, the teeth of two rotary members mesh together, and the rotary members are rotated in opposite directions to grind the tissue. The rotary members may also be alternatingly moved up and down to perform initial dicing on the tissue. Once the tissue has been processed, the tissue may then be used in a therapeutic manner, such as by being incorporated with a scaffold and then implanted in the same patient from whom the tissue was originally harvested.11-17-2011
20100273258Interactive Microenvironment System - A culture cell for growing animal cells in vitro has sides and a bottom forming a volume. The volume contains a layer of nanofiber upon which animal cells can be cultured. The layer of nanofiber can be oriented or non-oriented. Multiple layers can be placed in the volume, where the layers have different composition and/or different porosity. The nanofiber can be, for example, surface treated or of a core-shell construction.10-28-2010
20110294210Microcarriers for Stem Cell Culture - We disclose a particle comprising a matrix coated thereon and having a positive charge, the particle being of a size to allow aggregation of primate or human stem cells attached thereto. The particle may comprise a substantially elongate, cylindrical or rod shaped particle having a longest dimension of between 50 μm and 400 μm, such as about 200 μm. It may have a cross sectional dimension of between 20 μm and 30 μm. The particle may comprise a substantially compact or spherical shaped particle having a size of between about 20 μm and about 120 μm, for example about 65 μm. We also disclose a method of propagating primate or human stem cells, the method comprising: providing first and second primate or human stem cells attached to first and second respective particles, allowing the first primate or human stem cell to contact the second primate or human stem cell to form an aggregate of cells and culturing the aggregate to propagate the primate or human stem cells for at least one passage. A method of propagating human embryonic stem cells (hESCs) in long term suspension culture using microcarriers coated in Matrigel or hyaluronic acid is also disclosed. We also disclose a method for differentiating stem cells.12-01-2011
20100197014METHODS FOR INCREASING DEFINITIVE ENDODERM PRODUCTION - Disclosed herein are methods for increasing the production of definitive endoderm cells from pluripotent stem cells. Also disclosed herein are agents capable of increasing definitive endoderm cell production.08-05-2010
20110189767METHODS OF PREPARING FEEDER CELLS-FREE, XENO-FREE HUMAN EMBRYONIC STEM CELLS AND STEM CELL CULTURES PREPARED USING SAME - The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.08-04-2011
20100062526OPTIMIZED MESSENGER RNA - The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.03-11-2010
20080311655Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation - Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.12-18-2008
20100112688Screening Methods for Compounds that Modulate the Activity of G-Protein Coupled Receptors - The present invention relates to a screening system for modulators of GPCRs. Further it relates to recombinant vector systems for the heterologous expression of heterodimeric g-protein coupled receptors (GPCRs) in eucaryotic host cells. Preferably the functional expression of engineered GPCRs for the perception of sweet and L-amino acid taste or more preferably the use of said receptors for the identification of functional ligands is also encompassed.05-06-2010
20090023208Cultivation of Primate Embryonic Cells - The invention relates to methods for culturing human embryonic stem cells by culturing the stem cells in an environment essentially free of mammalian fetal serum and in a stem cell culture medium including amino acids, vitamins, salts, minerals, transferring, insulin, albumin, and a fibroblast growth factor that is supplied from a source other than just a feeder layer the medium. Also disclosed are compositions capable of supporting the culture and proliferation of human embryonic stem cells without the need for feeder cells or for exposure of the medium to feeder cells.01-22-2009
20100267136FABRICATION OF VASCULARIZED TISSUE USING MICROFABRICATED TWO-DIMENSIONAL MOLDS - Methods and materials for making complex, living, vascularized tissues for organ and tissue replacement, especially complex and/or thick structures, such as liver tissue is provided. Tissue lamina is made in a system comprising an apparatus having (a) a first mold or polymer scaffold, a semi-permeable membrane, and a second mold or polymer scaffold, wherein the semi-permeable membrane is disposed between the first and second molds or polymer scaffolds, wherein the first and second molds or polymer scaffolds have means defining microchannels positioned toward the semi-permeable membrane, wherein the first and second molds or polymer scaffolds are fastened together; and (b) animal cells. Methods for producing complex, three-dimensional tissues or organs from tissue lamina are also provided.10-21-2010
20100267134Isolation, characterization and differentiation of in vitro adult human germ line stem cells - A method of in vitro maturation of adult human germ line cells in an artificial biological environment, which entails: 10-21-2010
20080248567Methods and products for embryonic stem cell culture - The invention relates to methods and media for preparing and maintaining self-renewing pluripotent embryonic stem cells. The methods include, in some embodiments, culturing embryonic stem cells in culture medium that includes culture medium conditioned by cells that express wnt3a.10-09-2008
20080241921Method of promoting differentiation of one or more human stem cells into human coronary endothelial cells on a synthetic tubular structure - A method of promoting differentiation of one or more human stem cells into human coronary endothelial cells on at least one surface of a synthetic tubular structure to be used to make a human hybrid coronary graft is provided. The method includes arranging a plurality of human stem cells on the synthetic tubular structure to yield a hybrid stem cell/synthetic tubular structure and subjecting ex vivo, the hybrid stem cell/synthetic tubular structure to three dimensional dynamic conditions effective to promote differentiation of the one or more human stem cells into human coronary endothelial cells on the at least one surface.10-02-2008
20100279404METHOD OF NUCLEAR REPROGRAMMING - This invention provides a method of producing an induced pluripotent stem cell comprising the step of introducing at least one kind of non-viral expression vector (more preferably a plasmid vector) incorporating at least one gene that encodes a reprogramming factor into a somatic cell. An induced pluripotent stem cell wherein no exogenous genes induced is integrated into the cellular genome is also provided.11-04-2010
20130189778METHODS FOR THE PRODUCTION OF IPS CELLS USING NON-VIRAL APPROACH - Methods and composition of induction of pluripotent stem cells and other desired cell types are disclosed. For example, in certain aspects methods for generating essentially vector-free induced pluripotent stem cells are described. Furthermore, the invention provides induced pluripotent stem cells and desired cell types essentially free of exogenous vector elements with the episomal expression vectors to express differentiation programming factors.07-25-2013
20100124781Pluripotent Stem Cell Culture on Micro-Carriers - The present invention is directed to methods for the growth, expansion and differentiation of pluripotent stem cells on micro-carriers.05-20-2010
20110151555Compositions and methods for growing human embryonic cells - Methods for deriving and cultivating human embryonic stem (ES) cells and maintaining their pluripotency in culture is provided by utilizing secreted products obtained from the culture medium of human embryonic gem (EG) cell derivatives, such as embryoid body-derived cells. Substrates include compounds such as collagen I, fibronectin, or superfibronectin, or extracellular matrix, typically human derived.06-23-2011
20100120143INDUCTION OF APOPTOSIS AND CELL GROWTH INHIBITION BY PROTEIN 4.33 - There is disclosed an isolated cDNA sequence (SEQ ID NO:1) encoding a P4.33 polypeptide and comprising a coding region (SEQ ID NO:2) of the sequence described in SEQ ID NO:1, or a sequence having at least 90% homology with the coding region of SEQ ID NO:1. The P4.33 polypeptide functions as a specific cell-surface receptor for IGFBP-3, and undergoes nuclear translocation in combination with IGFBP-3. In particular aspects, IGFBP-3 and P4.33 (IGFBP-3R) cooperatively suppress DNA synthesis and cell growth, and induce caspase activation and apoptosis in cancer cells, indicating that P4.33 is an important mediator of IGF-independent growth inhibitory actions of IGFBP-3. The P4.33:IGFBP-3 system of the present invention can be used, inter alia, in screening and diagnostic assays, and for therapeutic methods for cancer treatment and tumor suppression.05-13-2010
20110195498LIQUID CRYSTALLINE SUBSTRATES FOR CULTURING CELLS - The present invention is directed to liquid crystalline substrates useful in the culture of cells and methods of their use. In certain embodiments, the invention provides methods and devices for imaging changes (e.g., reorganization) of extracellular matrix components by living cells.08-11-2011
20090263895Cell line for producing a non-retroviral vector - Provided are novel vectors and viral vectors capable of expressing exogenous gene or exogenous nucleic acid sequences in a target cell of interest, such as T cells, bone marrow cells, epithelial cells, liver cells and the like. The nucleic acid components of the vectors may include one or more native promoter/enhancer regions having modified sequence segments, one or more non-native promoter/enhancer or non-native promoter's gene or gene segment, and a native viral vector terminator or processing signal or segment thereof. The viral vectors comprise a virus or viral portion having on the surfaces or envelopes adsorption components, one for a packaging cell line and the other for delivery to a target cell. Other viral vectors provided by this invention have two components on their surfaces or envelopes, one of which is native to the virus and the other being non-native and capable of adsorbing to the target cell while being incapable of adsorbing to a native cell for the viral vector. Packaging cell lines for propagating the vectors and viral vectors are also provided, as are novel processes for propagating any of the disclosed vectors or viral vectors.10-22-2009
20090162932POLYPEPTIDE HAVING AN ACTIVITY TO SUPPORT PROLIFERATION OR SURVIVAL OF HEMATOPOIETIC STEM CELL OR HEMATOPOIETIC PROGENITOR CELL, AND DNA CODING FOR THE SAME - A gene encoding a polypeptide having an activity to support proliferation or survival of hematopoietic stem cells or hematopoietic progenitor cells is isolated by comparing expressed genes between cells which support proliferation or survival of hematopoietic stem cells or hematopoietic progenitor cells and cells which do not support the proliferation or survival. Proliferation or survival of hematopoietic stem cells or hematopoietic progenitor cells is supported by using stromal cells in which the isolated gene is expressed or a gene product of the isolated gene.06-25-2009
20130217118ADIPOSE-DERIVED STEM CELLS AND LATTICES - The present invention provides adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF) and adipose-derived lattices, alone and combined with the ADSCs of the invention. In one aspect, the present invention provides an ADSC substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The ADSCs can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the ADSCs can be expanded and cultured to produce molecules such as hormones, and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a adipose-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.08-22-2013
20110201110EFFICIENT METHOD FOR ESTABLISHING INDUCED PLURIPOTENT STEM CELLS - The present invention provides a method of producing induced pluripotent stem (iPS) cells, comprising bringing a nuclear reprogramming substance into contact with dental pulp stem cells. By using dental pulp stem cells as a source of somatic cells, the efficiency of establishment of human iPS cells by transfer of 3 or 4 factors can be improved dramatically. Additionally, dental pulp stem cells are easily available because they can be isolated and prepared from extracted wisdom teeth and teeth extracted because of periodontal disease and the like, so that they can be used widely as a source of somatic cells for iPS cell banks.08-18-2011
20110201109Ronin is Essential for Perpetuity of Mouse ES Cells, and Acts Independently of Canonical Pathways - The present invention, therefore, encompasses compositions and methods comprising Ronin, a Ronin activator, and methods of their use for maintaining the perpetuity of an ES cell phenotype.08-18-2011
20120295347Methods and Compositions for Producing Endothelial Progenitor Cells from Pluripotent Stem Cells - Aspects of the present invention are drawn to methods and compositions for producing endothelial progenitor cells (EPCs) in vitro from pluripotent stem cells and compositions containing such EPCs. The methods produce sufficient EPCs to use in therapeutic applications. In certain embodiments the EPCs are bipotent, giving rise to both vascular and lymphatic endothelial cells. In certain embodiments, EPCs express one or more of the following gene products: LYVE-1, PV-1/PAL-E, CD31, and CD34.11-22-2012
20120295346METHODS AND COMPOSITIONS FOR MODULATING MEMBRANE POTENTIAL TO INFLUENCE CELL BEHAVIOR - The present invention provides methods for controlling proliferation, differentiation, and/or migration of cells by modulating membrane potential through an endogenously expressed channel protein. The present invention also provides methods for identifying candidate instructor cells, as well as therapeutic agents that are useful for modulating (e.g., promote or inhibit) proliferation and differentiation, as well as promoting regeneration of a desired tissue type.11-22-2012
20090170193STEM CELLS - The present invention relates to an isolated stem cell population wherein said stem cells are CD34+, capable of self regeneration, capable of differentiation into ectodermal, mesodermal and endodermal cells and capable of adhering to tissue-culture grade plastic as well as to methods of isolation of said cells, methods of culturing and differentiation thereof, the progeny of such methods of differentiation as well as uses, including therapeutic uses of the stem cells and their differentiated progeny.07-02-2009
20090093055Islet Cells from Human Embryonic Stem Cells - This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine.04-09-2009
20090291496Neural Stem Cell Isolates from the Dental Papillary Annulus of Developing Teeth - Multipotent cranial neural crest stem cells and non-lineage committed precursor cells are described. The neural crest cells are capable of self-renewal, of being cultured into clonal spheroids including neurospheres, and of differentiation into neurons or other neuroepithelial cells. The non-lineage committed precursors are capable of differentiation into neurons, astrocytes and oligodendrocytes, and are capable of de-differentiation into induced pluripotent stem cells (iPSCs). Methods of obtaining, generating, isolating and culturing cranial neural crest stem cells and non-lineage committed precursor cells are also disclosed, including methods of providing a substantially pure in vitro cell culture consisting essentially of stem cells capable of multipotent differentiation and de-differentiation to a pluripotent state, which may be used for medical research or preserved for future therapeutic use by their autologous donor or a heterologous recipient.11-26-2009
20090275130BIOMIMETIC NUCLEIC ACIDS - The present invention is directed to nucleic acids with biomimetic properties and methods for producing said nucleic acids. In particular, this invention relates to nucleic acids exhibiting biomimetic properties in relation to proteins such as growth factors, hormones and/or other cell signaling proteins. Biomimetic properties may generally be defined as interactive ability in the same and/or similar manner as another biological molecule. This may, for example, include interacting with a ligand-binding biomolecule, such as a cell signaling receptor, in a manner similar to a native ligand. In the case of a signaling receptor, such biomimetic nucleic acids may in general act as an agonist or an antagonist to the given receptor. They may further act in competition to a native ligand.11-05-2009
20090275131METHOD FOR PRODUCTION OF MAST CELLS FROM STEM CELLS - Provided are methods for generating mast cells from pluripotent stem cells in vitro. Methods are disclosed for the differentiation of pluripotent cells, such as iPS cells and/or human embryonic stem cells, into mast cells. The resulting mast cells may be used for various purposes including screening cells for drug development and research. Growth factors which may be included in culture media according to the present invention include stem cell factor (SCF), FLT-3 ligand, thrombopoietin (TPO), interleukin-3 (IL-3), and/or interleukin-6 (IL-6).11-05-2009
20100279402Expression Construct for Digesting Aggregating Protein and Method of Inhibiting the Aggregation of Aggregating Protein - It is intended to provide a means which is efficacious in digesting a protein forming aggregates in a eukaryotic cell such as mutant superoxide dismutase 1 or an androgen receptor having an abnormally extended polyglutamine chain. Namely, an expression construct for digesting an aggregating protein which has a nucleic acid encoding an archaeal proteasome and being connected in an operable manner to a promoter for eukaryotic cells. By transferring this expression construct into a eukaryotic cell, the aggregating protein is digested owing to the action of the archaeal proteasome.11-04-2010
20100279405SYSTEMS, METHODS AND COMPOSITIONS FOR OPTIMIZING TISSUE AND CELL ENRICHED GRAFTS - Disclosed herein are methods and systems for the concentration of cells from a cell suspension into unprocessed tissue, such as adipose tissue. Also disclosed herein are systems for optimizing hydration of tissue and cell enriched grafts.11-04-2010
20090291494Differentiation of Multi-Lineage Progenitor Cells to Pancreatic Cells - Fetal blood multi-lineage progenitor cells that are capable of a wide spectrum of transdifferentiation are described, as well as methods of differentiating the progenitor cells into pancreatic cells.11-26-2009
20090291495Neural Cell Populations from Primate Pluripotent Stem Cells - This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.11-26-2009
20130217117PLURIPOTENT STEM CELLS OBTAINED BY NON-VIRAL REPROGRAMMING - Methods for reprogramming primate somatic cells to pluripotency using an episomal vector that does not encode an infectious virus are disclosed. Pluripotent cells produced in the methods are also disclosed.08-22-2013
20100279403DIFFERENTIATION OF PLURIPOTENT CELLS - Provided herein are methods for the in vitro maintenance, expansion, culture, and/or differentiation of pluripotent cells, such as human embryonic stem cells (hESC) or induced pluripotent cells (iPSC), into hematopoietic precursor cells or endothelial cells. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the pluripotent cells into hematopoietic precursor cells or endothelial cells. The resulting hematopoietic precursor cells may be further differentiated into various myeloid or lymphoid lineages.11-04-2010
20080241919Defined media for pluripotent stem cell culture - Stem cells, including mammalian, and particularly primate primordial stem cells (pPSCs) such as human embryonic stem cells (hESCs), hold great promise for restoring cell, tissue, and organ function. However, cultivation of stem cells, particularly undifferentiated hESCs, in serum-free, feeder-free, and conditioned-medium-free conditions remains crucial for large-scale, uniform production of pluripotent cells for cell-based therapies, as well as for controlling conditions for efficiently directing their lineage-specific differentiation. This instant invention is based on the discovery of the formulation of minimal essential components necessary for maintaining the long-term growth of pPSCs, particularly undifferentiated hESCs. Basic fibroblast growth factor (bFGF), insulin, ascorbic acid, and laminin were identified to be both sufficient and necessary for maintaining hESCs in a healthy self-renewing undifferentiated state capable of both prolonged propagation and then directed differentiation. Having discerned these minimal molecular requirements, conditions that would permit the substitution of poorly-characterized and unspecified biological additives and substrates were derived and optimized with entirely defined constituents, providing a “biologics”-free (i.e., animal-, feeder-, serum-, and conditioned-medium-free) system for the efficient long-term cultivation of pPSCs, particularly pluripotent hESCs. Such culture systems allow the derivation and large-scale production of stem cells such as pPSCs, particularly pluripotent hESCs, in optimal yet well-defined biologics-free culture conditions from which they can be efficiently directed towards a lineage-specific differentiated fate in vitro, and thus are important, for instance, in connection with clinical applications based on stem cell therapy and in drug discovery processes.10-02-2008
20080233640Prostate Stem Cell - We describe a method for the isolation of prostate stem cells, typically prostate stem cells which express CD 133 antigen; stem cells and cancer stem cells isolated by the method and their use.09-25-2008
20080286862Physiochemical Culture Conditions for Embryonic Stem Cells - Physiochemical parameters to improve the culturing and sub-culturing (here called cloning) of human embryonic stem cells have been investigated. Low levels of oxygen and higher than expected levels of osmolarity in the culture medium have both been found to contribute to the improved culture of human stem cells.11-20-2008
20100216236Nuclear reprogramming factor and induced pluripotent stem cells - The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including screening and testing methods as well as methods of stem cell therapy. The present invention also relates to somatic cells derived by inducing differentiation of the aforementioned iPS cells.08-26-2010
20090137040METHODS FOR MAKING AND USING REPROGRAMMED HUMAN SOMATIC CELL NUCLEI AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS - Activated human embryos produced by therapeutic cloning can give rise to human totipotent and pluripotent stem cells from which autologous cells for transplantation therapy are derived. The present invention provides methods for producing activated human embryos that can be used to generate totipotent and pluripotent stem cells from which autologous cells and tissues suitable for transplantation can be derived. In one embodiment, the invention provides methods for producing activated human embryos by parthenogenesis; in another embodiment, the invention provides methods for producing activated human embryos by somatic cell nuclear transfer whereby the genetic material of a differentiated human donor cell is reprogrammed to form a diploid human pronucleus capable of directing a cell to generate the stem cells from which autologous, isogenic cells for transplantation therapy are derived. The ability to create autologous human embryos represents a critical step towards generating immune-compatible stem cells that can be used to overcome the problem of immune rejection in regenerative medicine. The activated human embryos produced by the present invention also provide model systems for identifying and analyzing the molecular mechanisms of epigenetic imprinting and the genetic regulation of embryogenesis and development.05-28-2009
20090137038METHODS OF PROLIFERATING STEM CELLS - The invention relates to methods of proliferating stem cells. More particularly, the invention relates to the use of glycosaminoglycans or proteoglycans to promote the growth of stem cells in ex vivo culture, while preserving their multipotentiality.05-28-2009
20090142831PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.06-04-2009
20080318312PANCREATIC ISLET TRANSCRIPTION FACTOR AND USES THEREOF - The present invention provides a pancreatic islet transcription factor and methods of treating and diagnosing diabetes.12-25-2008
20130217119MODULAR DNA-BINDING DOMAINS AND METHODS OF USE - The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.08-22-2013
20090325288METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIOMYOCYTES - The present invention provides a method for inducing differentiation of cardiomyocytes efficiently and selectively from stem cells.12-31-2009
20090298170HEPATOCYTE LINEAGE CELLS - Disclosed herein are methods for producing liver precursor cells as well as hepatocyte cells form pluripotent and/or multipotent cells. Also disclosed herein are methods of enriching isolating and/or purifying liver precursor cells and/or hepatocyte cells. Further disclosed are compositions comprising cell cultures and cell populations that are enriched for liver precursor cells or hepatocyte cells.12-03-2009
20080233641Simultaneous modulation of multiple genes - Disclosed herein are compositions and methods that regulate expression of two or more endogenous genes.09-25-2008
20120070896METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS AND METHOD FOR CULTURING THE SAME - [Object] To provide a technology for production of safer iPS cells and to provide a more efficient technology for culturing iPS cells.03-22-2012
20090191627SYNTHETIC SURFACES FOR CULTURING CELLS IN CHEMICALLY DEFINED MEDIA - Synthetic surfaces capable of supporting culture of eukaryotic cells including stem cells and undifferentiated human embryonic stem cells in a chemically defined medium include a swellable (meth)acrylate layer and a polypeptide conjugated to the swellable (meth)acrylate layer. The swellable (meth)acrylate layer may be formed by polymerizing monomers in a composition that includes a carboxyl group-containing (meth)acrylate monomer, a cross-linking (di- or higher-functional) (meth)acrylate monomer, and a hydrophilic monomer capable of polymerizing with the carboxyl group-containing (meth)acrylate monomer and the cross-linking (meth)acrylate monomer. The swellable (meth)acrylate layer has an equilibrium water content in water of between about 5% and about 70%. The conjugated peptide may include an RGD amino acid sequence.07-30-2009
20090053805POST-PARTUM MAMMALIAN PLACENTA, ITS USE AND PLACENTAL STEM CELLS THEREFROM - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.02-26-2009
20090215171PELCAM-1-related molecules compositions kit of parts and associated methods of use - An isolated polynucleotide coding for platelet endothelial cell adhesion molecule-1 (PECAM-1), and obtainable by amplifying cDNA from total human white blood cells by PCR; peptides encoding PECAM-1 508-27-2009
20090137039TARGETING OPPOSITE STRAND REPLICATION INTERMEDIATES OF SINGLE-STRANDED VIRUSES BY RNAI - The invention relates to methods and compositions for modulating viral replication through double-stranded RNA-mediated gene silencing (RNAi), wherein the antiviral methods and compositions preferentially target opposite strand replication intermediates of single-stranded RNA viruses.05-28-2009
20110223660COMPOSITIONS FOR INDUCING DIFFERENTIATION INTO RETINAL CELLS FROM RETINAL PROGENITOR CELLS OR INDUCING PROLIFERATION OF RETINAL CELLS COMPRISING WNT SIGNALING PATHWAY ACTIVATORS - Disclosed is a composition for inducing the proliferation of retinal cells or the differentiation of retinal progenitor cells into retinal cells. The composition, similar to in vivo conditions for development during embryogenesis, induces stem cells to differentiate into a multitude of photoreceptor cells at high yield within a short period of time, without an additional gene transfer. In addition, the differentiated photoreceptor cells are useful in cellular therapy because they, when transplanted into degenerated or injured retinas, can be engrafted and fused within the retinas to prevent or cure retinal degeneration.09-15-2011
20090221068Cell Cultivation Method and Cell Culture - Provided is a cell cultivation method in which the cell is cultured using a peptide hydrogel as a scaffold, for carrying out high-dimensional culture of a cell such as porcine hepatocyte, human hepatocyte, porcine pancreatic islet or human pancreatic islet for a long period under conditions where cell survival, cell morphology and cell functions are maintained. Also provided are a cell culture including a cell and a peptide hydrogel obtained by the above-described cultivation method, a bioreactor including the cell culture, and a cell preparation including the cell culture.09-03-2009
20100248362Apparatus and Methods for Sorting Particles - A multi-channel apparatus for classifying particles according to one or more particle characteristics. The apparatus comprises a plurality of flow cytometry units, each of which is operable to classify particles in a mixture of particles by interrogating a stream of fluid containing the particles with a beam of electromagnetic radiation. The flow cytometry units share an integrated platform comprising at least one of the following: (1) a common supply of particles; (2) a common housing; (3) a common processor for controlling operation of the units; (4) a common processor for receiving and processing information from the units; and (5) a common fluid delivery system. The integrated platform can include a common source of electromagnetic radiation. A method of the invention comprises using a plurality of flow cytometry units sharing the integrated platform to perform a flow kilometric operation, such as analyzing or sorting particles.09-30-2010
20090258421EMBRYONIC STEM CELLS AND NEURAL PROGENITOR CELLS DERIVED THEREFROM - The present invention provides undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, and committed progenitor cells such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and/or glial cells and uses thereof. The invention also provides methods that generate in vitro and in vivo models of controlled differentiation of ES cells towards the neural lineage. The model, and the cells that are generated along the pathway of neural differentiation may be used for the study of the cellular and molecular biology of human neural development, for the discovery of genes, growth factors, and differentiation factors that play a role in neural differentiation and regeneration, for drug discovery and for the development of screening assays for teratogenic, toxic and neuroprotective effects.10-15-2009
20120142096FUSION PROTEINS OF HIV REGULATORY/ACCESSORY PROTEINS - The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections.06-07-2012
20100184212HUMAN EMBRYONIC STEM CELL DERIVED MESODERM-LIKE EPITHELIUM TRANSITIONS TO MESENCHYMAL PROGENITOR CELLS - Human embryonic stem cells (hESC) have the potential to produce all of the cells in the body. They are also able to self-renew indefinitely, sparking the hope they could be used as a source for large scale production of therapeutic cell lines. The present invention relates to a monolayer differentiation culture system that induces hESC (WA09 and BG01) to form epithelial sheets with mesodermal gene expression patterns (BMP4, RUNX1, GAT A4). These E-cadherin+ CD90lovv cells then undergo apparent epithelial-mesenchymal transformation (EMT) for the derivation of mesenchymal progenitor cells (hES-MC) that by flow cytometry are negative for hematopoietic (CD34, CD45 and CD 133) and endothelial (CD31 and CD 146) markers, but positive for markers associated with mesenchymal stem cells (MSC) (CD73, CD90, CD105 and CD166). To determine their functionality, we tested their capacity to produce the three lineages commonly associated with MSC and found they could form osteogenic and chondrogenic, but not adipogenic lineages. The derived hES-MC were able to remodel and contract collagen I lattice constructs to an equivalent degree as keloid fibroblast control cells and were induced to express αSMA when exposed to TGF-β1, but not PDGF-B. This data suggests the derived hES-MC cells are multipotent cells with potential uses in tissue engineering/regenerative medicine and for providing a highly reproducible cell source for adult-like progenitor cells.07-22-2010
20130122589TARGETED DIFFERENTIATION OF STEM CELLS - The invention provides a method of producing a mesodermal lineage progenitor cell, by 10 application of one or more factors selected from the group consisting of activin, Wnt, BMP, FGF, an inhibitor of activin, GDF and NT to a culture of undifferentiated stem cells for a period of time sufficient to differentiate a stem cell into a mesodermal lineage progenitor cell. The stem cell may be derived from a stem cell line, such as an embryonic stem cell line, for example HUES-1, HUES-7, HUES-8, MAN-1 or MAN-2. Also provided are cell 1 cultures, cells, matrices, kits and uses of the cell cultures and cells.05-16-2013
20100190248Methods for the Cryopreservation of Animal Cells that Contain High Levels of Intracellular Lipids - A method for cryopreservation of animal cells with high level of intracellular lipid content, comprises the steps of conducting a delipation procedure using one or more lipolytic agent(s) and/or lipogenesis inhibitors during culture of the animal cells to stimulate the hydrolysis of intracellular lipids to reduce the lipid content, and vitrifying the treated animal cells using a modified vitrification solution and a modified warming solution.07-29-2010
20110129918METHOD FOR EXPANDING MESENCHYMAL STEM CELLS IN LOW-DENSITY AND HYPOXIC CULTURE - The present invention relates to a novel method for expanding mesenchymal stem cells (MSCs) in low-density and hypoxic condition as compared to normal air conditions traditionally used in cell culture. The present method provides rapid and efficient expansion of human MSCs without losing cellular proliferation and stem cell properties, including increase in proliferation, decrease in senescence, and increase in differentiation potential both in vitro and in vivo. The expanded MSCs by the present method may maintain normal karyotyping, and will not form tumor when transplanted into mamma.06-02-2011
20120196360METHOD OF EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS - Provided is a method of producing an iPS cell, comprising bringing (a) Oct3/4 or a nucleic acid that encodes the same, (b) Klf4 or a nucleic acid that encodes the same, and (c) Sox2 or a nucleic acid that encodes the same, as well as (d1) L-Myc or a nucleic acid that encodes the same and/or (d2) a functional inhibitor of p53, into contact with a somatic cell. It is preferable that (a) a nucleic acid that encodes Oct3/4, (b) a nucleic acid that encodes Klf4, (c) a nucleic acid that encodes Sox2, (d1) a nucleic acid that encodes L-Myc and (e) a nucleic acid that encodes Lin28 or Lin2808-02-2012
20100221829Media for culturing stem cells - Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.09-02-2010
20100240126DEVELOPMENT OF UNIVERSAL CANCER DRUGS AND VACCINES - This invention generally relates to a design and method for developing novel anti-tumor/cancer drugs, vaccines and therapies, using microRNA (miRNA) and its shRNA homologues/derivatives. More particularly, the present invention relates to the use of a nucleic acid composition capable of expressing mir-302-like gene silencing effectors upon delivery into human cells and then silencing mir-302-targeted cell cycle regulators and oncogenes, resulting in an inhibitory effect on tumor/cancer cell growth and metastasis. Mir-302 is the most predominant miRNA found in human embryonic stem (hES) and induced pluripotent stem (iPS) cells, yet its function is unclear. The present invention establishes that in humans mir-302 concurrently suppressed both cyclin-E-CDK2 and cyclin-D-CDK4/6 pathways and eventually blocked over 70% of the G1-S transition. Simultaneously, mir-302 also silences BMI-1, a cancer stem cell marker, and subsequently promotes the tumor suppressor functions of p16Ink4a and p14/p19Arf in inhibiting CDK4/6-mediated cell proliferation. Therefore, the present invention for the first time reveals the tumor suppressor function of mir-302 in humans. This novel finding advances the design and method for developing new cancer drugs, vaccines and therapies directed against multiple kinds of human tumors and cancers, in particular including, but not limited, malignant skin, prostate, breast and liver cancers as well as various tumors.09-23-2010
20100227399SOFT GEL SYSTEMS IN MODULATING STEM CELL DEVELOPMENT - This invention provides gels and matrices having a rigidity in the range of 150-750 Pa, methods of manufacturing same, and method of preserving a mesenchymal stem cell population or studying mesenchymal stem cells, comprising same.09-09-2010
20130217120PLACENTA-DERIVED CELL-CONDITIONED CULTURE MEDIA AND ANIMAL-FREE, FEEDER-FREE METHOD FOR CULTURING STEM CELLS USING THE SAME - Disclosed are placenta-derived cell-conditioned culture media for stem cells. An animal-free, feeder-free method using the media is also provided for culturing stem cells. The media can prevent the stem cells from being contaminated with xenogeneic proteins or cells, and maintain human embryonic stem cells in an undifferentiated state for a long period of time in vitro with an economic benefit.08-22-2013
20090253202DEFINITIVE ENDODERM - Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.10-08-2009
20090042286USE OF THE ACA GLYCOPROTEIN FOR OBTAINING/MAINTAINING PLURIPOTENT NON-EMBRYONIC STEM CELLS - Described is the use of a glycosylphosphatidylinositol (GPI)-anchored glycoprotein ACA or activator of ACA for obtaining pluripotent non-embryonic stem cells or for maintaining the pluripotenial phenotype of non-embryonic stem cells.02-12-2009
20090075374METHODS OF GENERATING EPITHELIAL LINEAGE CELLS FROM EMBRYOID BODIES AND PLURIPOTENT CELLS - Methods of generating p63-positive cells from embryoid bodies and pluripotent cells by culturing the cells in the presence of a retinoid and optionally a bone morphogenetic protein, such that the cells express at least p63. The p63-positive cells can be further cultured without the retinoid and optional bone morphogenetic protein to K14-positive cells. The K14-positive cells can be further cultured into various terminally differentiated cell types of the epithelial lineage.03-19-2009
20090075373Neural progenitor cells derived from embryonic stem cells - The present invention relates to undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, as well as committed progenitor cells such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and/or glial cells and uses thereof.03-19-2009
20120034692ENDOCRINE PRECURSOR CELLS, PANCREATIC HORMONE-EXPRESSING CELLS AND METHODS OF PRODUCTION - Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.02-09-2012
20120142095TECHNIQUE FOR DETERMINING THE STATE OF A CELL AGGREGATION IMAGE PROCESSING PROGRAM AND IMAGE PROCESSING DEVICE USING THE TECHNIQUE, AND METHOD FOR PRODUCING A CELL AGGREGATION - An image processing program (GP) attains (S06-07-2012
20120142094GENERATING IPS CELLS BY PROTEIN TRANSDUCTION OF RECOMBINANT POTENCY-DETERMINING FACTORS - The present invention relates generally to compositions and methods for reprogramming a primate somatic cell to a higher potency level. Specifically, the invention includes compositions which comprise a recombinant polypeptide that is a potency-determining factor and methods of reprogramming a primate somatic cell to a higher potency level under conditions that allow sufficient amount of the polypeptide delivered into the primate somatic cell.06-07-2012
20120142097FUSION PROTEINS OF HIV REGULATORY/ACCESSORY PROTEINS - The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections.06-07-2012
20100184213APOCRINE CELL LINE - An apocrine cell line is obtained by the steps of isolating an apocrine cell from primary tissue, culturing the isolated cell in a first culture medium, removing unattached cells from the first culture medium and transferring said unattached cells to a second culture medium comprising an effective concentration of a phorbol ester, and thereby establishing an apocrine cell line exhibiting long-term proliferation capability, which after many cultures is indicative of indefinite proliferation.07-22-2010
20090104696Methods and Compositions for Feeder-Free Pluripotent Stem Cell Media Containing Human Serum - The present invention provides compositions and methods for the culture and maintenance of pluripotent stem cells. More particularly, the present invention provides for compositions and methods for culturing, maintaining, growing and stabilizing primate pluripotent stem cells in a feeder-free defined media further comprising human serum, or a soluble attachment component of the human serum, for promoting cell attachment.04-23-2009
20100297756MEANS FOR DELIVERY OF NUCLEIC ACIDS ACTIVE FOR GENE SILENCING USING SYNTHETIC POLYMERS - The invention relates to a composition useful as transfection agent, comprising polyamines modified by aromatic amino acids and small double-strand or single-strand RNA active for RNA interference.11-25-2010
20110111497CELL SEPARATION APPARATUS, METHOD FOR ACTIVATING FAT-DERIVED CELLS, GRAFT MATERIAL PRODUCING PROCESS, AND GRAFT MATERIAL - The therapeutic effect of a final product is improved while guaranteeing sterility. Provided is a cell separation apparatus comprising a decomposition treatment unit for producing a cell suspension by digesting living body tissue to release living body-derived cells from the living body tissue; a cell concentrating unit for generating a cell-concentrated solution by concentrating the cell suspension by centrifugation; and a efficiency-increasing mechanism for increasing the efficiency of the living body-derived cells contained in the cell-concentrated solution.05-12-2011
20100055783NUCLEIC ACID COMPOUNDS FOR INHIBITING RAS GENE EXPRESSION AND USES THEREOF - The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing RAS (e.g., HRAS, KRAS, NRAS) gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an HRAS, KRAS, or NRAS mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a RAS gene in a cell or in a subject to treat a RAS-related disease.03-04-2010
20100297755 Method for Differentiating of Human Embryonic Stem Cells Into the Osteoblastic Lineage - Disclosed are a composition for introducing the osteogenic differentiation of human embryonic stem cells and a method for differentiating human embryonic stem cells into an osteoblastic lineage by inhibiting the mTOR signaling pathway. When cultured in the presence of an inhibitor of the mTOR signaling pathway, human embryonic stem cells are effectively induced to differentiate into an osteoblastic lineage. The osteogenic differentiation of human embryonic stem cells using the method and the composition is useful in examining the development and differentiation mechanism of osteoblasts and the cause of metabolic bone diseases, including osteoporosis. In addition, the method and the composition can be applied to the development of osteogenic differentiation techniques for generating clinically useful, terminally differentiated mature cells or progenitor cells.11-25-2010
20100311163CELL TRANSFORMED BY HUMAN WNT3A GENE - Disclosed is a cell transformed by a vector containing human Wnt3a gene, wherein the cell is selected from a group consisting of hair follicle-derived cells and prostate cancer-derived cells.12-09-2010
20100311164METHODS AND COMPOSITIONS FOR FEEDER-FREE PLURIPOTENT STEM CELL MEDIA CONTAINING HUMAN SERUM - The present invention provides compositions and methods for the culture and maintenance of pluripotent stem cells. More particularly, the present invention provides for compositions and methods for culturing, maintaining, growing and stabilizing primate pluripotent stem cells in a feeder-free defined media further comprising human serum, or a soluble attachment component of the human serum, for promoting cell attachment.12-09-2010
20100304479METHOD OF MAKING A HAIR AND BIOLOGICAL MATERIAL - A method of making a hair, including a step of culturing an undifferentiated cell of a mammal to produce an embryoid body and a step of further culturing the embryoid body is provided, wherein the culturing step is to culture the embryoid body on a three-dimensional matrix for 5 to 12 days. Furthermore, a biological material obtainable by the method of making a hair as described above is provided. Moreover, a biological material for a screening system of evaluating a medical product or the like, obtainable by utilizing the method of making a hair as described above is provided.12-02-2010
20100304481MEDIUM AND CULTURE OF EMBRYONIC STEM CELLS - Previous methods for culturing primate pluripotent stem cells have required either fibroblast feeder cells or a medium which was exposed to fibroblast feeder cells to maintain the stem cells in an undifferentiated state. It has now been found that high levels of fibroblast growth factor in a medium together with at least one of gamma aminobutyric acid, pipecolic acid, and lithium, enables pluripotent stem cells to remain undifferentiated indefinitely through multiple passages, even without feeder cells or conditioned medium. Without beta-mercaptoethanol, the medium improves cloning efficiency. Also, a matrix of human proteins can be used to culture the undifferentiated cells without exposing the cells to animal products. Further disclosed are new primate pluripotent cell lines made using the defined culture conditions, including the medium and the matrix. Such new cell lines will have never been exposed to animal cells, animal products, feeder cells or conditioned medium.12-02-2010
20100304480Hematopoietic Fingerprints: Methods of Use - The present invention is related to the discovery that the detection of one or more biomarkers in a body sample can identify hematapoietic progenitors that are precursors to a specific blood cell lineage. The methods of the present invention are also directed to the detection of the dysregulation of these biomarkers as a diagnostic assay for the certain disease states, such as cancer.12-02-2010
20100304482SWELLABLE SYNTHETIC MICROCARRIERS FOR CULTURING CELLS - A cell culture microcarrier includes a polymer formed from copolymerization of a mixture including (i) an uncharged hydrophilic unsaturated monomer having a hydroxyl group; (ii) a hydrophilic carboxylic acid containing unsaturated monomer; and (iii) a hydrophilic multifunctional unsaturated monomer. The microcarrier may further include a polypeptide, such as a polypeptide that promotes cell adhesion, conjugated to the surface of the microcarrier; e.g. via the carboxyl group from the hydrophilic carboxylic acid containing unsaturated monomer. Some of the microcarriers support attachment of human embryonic stem cells.12-02-2010
20090081782Methods for vitrification of human oocytes - Provided are methods for the vitrification of human oocytes, which comprises: (a) placing human oocytes on a transfer instrument; and (b) placing the transfer instrument and the human oocytes directly into a slushed nitrogen (N03-26-2009
20120021511PREPRIMITIVE STREAK AND MESENDODERM CELLS - This disclosure relates to compositions comprising human preprimitive streak cells and/or human mesendoderm cells as well as methods for their production. Additionally, disclosed herein are methods of identifying factors useful in the further differentiation of preprimitive streak and mesendoderm cell types.01-26-2012
20110111499MESENCHYMAL STEM CELL AND METHOD FOR PRODUCTION THEREOF - The present invention provides a method for producing a mesenchymal stem cell having an ability to differentiate into a myoblast by culturing a pluripotent stem cell derived from a human or animal, including: i) preparing the pluripotent stem cell that has been cryopreserved, ii) sub-culturing the prepared pluripotent stem cell in an undifferentiated state for a prescribed number of times, iii) culturing the subcultured pluripotent stem cell under conditions that enable induction of differentiation into an adipocyte in vitro, and iv) separating and collecting a CD105-positive cell during the culturing process.05-12-2011
20100233806CARBOCYCLIC BICYCLIC NUCLEIC ACID ANALOGS - Provided herein are saturated and unsaturated carbocyclic bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using these oligomeric compounds. The saturated and unsaturated carbocyclic bicyclic nucleosides are useful for enhancing properties of oligomeric compounds including nuclease resistance.09-16-2010
20110008887EPHA4-POSITIVE HUMAN ADULT PANCREATIC ENDOCRINE PROGENITOR CELLS - The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stem cells having a high propensity to differentiate into insulin-producing cells or into insulin-producing cell aggregates.01-13-2011
20110008886METHODS AND MATERIALS FOR ISOLATING ISOGENIC ISLET CELLS - Compositions and methods for isolating and purifying islet cells are described. Islets obtained using such compositions and methods can be transplanted into diabetic patients.01-13-2011
20100184214METHOD FOR PRODUCTION OF DENDRITIC CELL - The present invention provides methods for producing DCs, which comprise the step of culturing DC precursor cells in the presence of multiple cytokines, dendritic cells produced thereby, and uses thereof. The methods of the present invention enable production of large quantities of DC precursors with a high ability to differentiate into DCs. The present invention enables one to obtain large quantities of DCs from a small number of DC precursor cells, and therefore makes it easier to increase the number of DCs for administration in DC-based anti-tumor immunotherapy, treatment of infection, and such. Thus, an enhancement is expected for the effect of DC vaccines.07-22-2010
20110033928METHODS AND COMPOSITIONS FOR GROWTH OF CELLS AND EMBRYONIC TISSUE ON A SYNTHETIC POLYMER MATRIX - The present invention provides methods and compositions for establishing and maintaining growth of cells and embryonic tissue on a synthetic polymer matrix. For example, the present invention provides synthetic growth matrices for stem cells, gametes, mature differentiated cells, and embryonic tissue (e.g., blastomeres, embryos, and embryoid bodies). In certain embodiments, the cells are capable of going through multiple passages while remaining in an undifferentiated state as a result of the synthetic polymer matrix.02-10-2011
20110111498Microcarriers for Stem Cell Culture - We disclose a particle comprising a matrix coated thereon and having a positive charge, the particle being of a size to allow aggregation of primate or human stem cells attached thereto. The particle may comprise a substantially elongate, cylindrical or rod shaped particle having a longest dimension of between 50 μm and 400 μm, such as about 200 μm. It may have a cross sectional dimension of between 20 μm and 30 μm. The particle may comprise a substantially compact or spherical shaped particle having a size of between about 20 μm and about 120 μm, for example about 65 μm. We also disclose a method of propagating primate or human stem cells, the method comprising: providing first and second primate or human stem cells attached to first and second respective particles, allowing the first primate or human stem cell to contact the second primate or human stem cell to form an aggregate of cells and culturing the aggregate to propagate the primate or human stem cells for at least one passage. A method of propagating human embryonic stem cells (hESCs) in long term suspension culture using microcarriers coated in Matrigel or hyaluronic acid is also disclosed. We also disclose a method for differentiating stem cells.05-12-2011
20110117645METHOD FOR PROLIFERATION OF PLURIPOTENT STEM CELLS - For efficient proliferation of pluripotent stem cells in a system free from any animal-derived material such as feeder cells or serum, the present invention provides a method for proliferation of pluripotent stem cells, which comprises culturing the pluripotent stem cells in a medium free from both feeder cells and serum in a system containing laminin-5.05-19-2011
20100144033Suspension Culture of Human Embryonic Stem Cells - This disclosure provides an improved system for culturing human embryonic stem cells. The cells are cultured in suspension so as to maximize the production capacity of the culture environment. The new culture system of this invention allows for bulk proliferation of hES cells in a more cost-effective manner, which facilitates commercial production of important products for use in human therapy.06-10-2010
20110086424METHODS FOR PRODUCING ENUCLEATED ERYTHROID CELLS DERIVED FROM PLURIPOTENT STEM CELLS - Methods for generating enucleated erythroid cells using pluripotent stem cells are provided. The methods permit the production of large numbers of cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Methods for generating megakaryocyte and platelets are also provided.04-14-2011
20110244566Enhanced efficiency of induced pluripotent stem cell generation - Human somatic cells are reprogrammed to become induced pluripotent stem cells (iPS cells) by the introduction of a minicircle DNA vector. Cells of interest include adipose stem cells.10-06-2011
20110244565Method Of Collecting Particles From A Sample Fluid - A method is provided for collecting a concentration of particles from a sample fluid containing the particles. The method includes the steps of providing a microfluidic device. The microfluidic device includes an input channel, an output channel and a collection region. The input channel has an input end and an output end. The output channel has an input end and an output end. The collection region interconnects the output end of the input channel and the input end of the output channel. The sample fluid flows through the input channel and the output channel at a first velocity and through the collection region at a second velocity less than the first velocity such that the particles collect in therein.10-06-2011
20110143433Microcarriers for Stem Cell Culture - We disclose a particle comprising a matrix coated thereon and having a positive charge, the particle being of a size to allow aggregation of primate or human stem cells attached thereto. The particle may comprise a substantially elongate, cylindrical or rod shaped particle having a longest dimension of between 50 μm and 400 μm, such as about 200 μm. It may have a cross sectional dimension of between 20 μm and 30 μm. The particle may comprise a substantially compact or spherical shaped particle having a size of between about 20 μm and about 120 μm, for example about 65 μm. We also disclose a method of propagating primate or human stem cells, the method comprising: providing first and second primate or human stem cells attached to first and second respective particles, allowing the first primate or human stem cell to contact the second primate or human stem cell to form an aggregate of cells and culturing the aggregate to propagate the primate or human stem cells for at least one passage. A method of propagating human embryonic stem cells (hESCs) in long term suspension culture using microcarriers coated in Matrigel or hyaluronic acid is also disclosed. We also disclose a method for differentiating stem cells.06-16-2011
20100216237OPTIMIZED AND DEFINED METHOD FOR ISOLATION AND PRESERVATION OF PRECURSOR CELLS FROM HUMAN UMBILICAL CORD - The present invention refers to an optimized and defined method for isolation and preservation of precursor cells from human umbilical cord. Besides being reproducible and 100% reliable, in terms of the number of samples processed, the method results in a high and defined number of precursor cells, being the majority obtained after a single adhesion and expansion/multiplication phase ex vivo (thus granting cell phenotype), in a shorter time frame than what was previously described in the state-of-the-art. With this method, it is possible to obtain, in 9 days, after direct freezing of a cell fraction, and after one expansion/multiplication phase ex vivo (end of P0) of the majority of the cells, about 8.6(±0.1)×1008-26-2010
20110086423Cellular Targets for Treatment of Retroviral Infection - Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.04-14-2011
20090311781METHODS OF EXPANDING EMBRYONIC STEM CEELS IN A SUSPENSION CULTURE - A method of expanding and maintaining human embryonic stem cells (ESCs) in an undifferentiated state by culturing the ESCs in a suspension culture under culturing conditions devoid of substrate adherence is provided. Also provided are a method of deriving ESC lines in the suspension culture and methods of generating lineage-specific cells from ESCs which were expanded in the suspension culture of the present invention.12-17-2009
20090029465Culturing Human Embryonic Stem Cells - Previous methods for culturing human embryonic stem cells have required either fibroblast feeder cells or a medium which has been exposed to fibroblast feeder cells in order to maintain the stem cells in an undifferentiated state. It has now been found that if high levels of fibroblast growth factor are used in a medium with gamma amino butyric acid, pipecholic acid, lithium and lipids, the stem cells will remain undifferentiated indefinitely through multiple passages, even without feeder cells or conditioned medium. A humanized matrix of human proteins can be used as a basement matrix to culture the cells. New lines of human embryonic stem cells made using these culture conditions, the medium and the matrix, will never have been exposed to animal cells, animal products, feeder cells or conditioned medium.01-29-2009
20100062525OPTICALLY RESPONSIVE AND MECHANICALLY TUNABLE COLLOID-IN-LIQUID CRYSTAL GELS - Colloidal liquid crystal gels (CLCGs), sensors incorporating the CLCGs, culture substrates made from the CLCGs, and patterned films and molded articles made from the CLCGs are provided. The CLCGs are composite liquid crystal materials comprising networks of particles having liquid crystal domains dispersed therein.03-11-2010
20100068805XENO-FREE CULTURE CONDITIONS FOR HUMAN EMBRYONIC STEM CELLS AND METHODS THEREOF - The present disclosure provides novel culture system and methods for culturing and propagating hESCs in a substantially undifferentiated state for several passages. The ability to grow such cells without differentiation has important applications for therapeutic uses of ES cells for treating human disorders using tissue transplantation and/or gene therapy techniques. In particular, the disclosure further relates to conditioned medium obtained from human germ lineage derived feeder cells (GLDF). The hESC lines are derived, cultured and propagated in substantially undifferentiated state using the conditioned media from GLDF cells of the disclosure. In particular, the disclosure relates to the xeno-free derivation, culture and propagation of hESCs using conditioned medium of GLDF cells obtained thereof.03-18-2010
20100055784NUCLEIC ACID COMPOUNDS FOR INHIBITING WNT GENE EXPRESSION AND USES THEREOF - The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing WNT1, WNT2, or WNT3A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a WNT1, WNT2, or WNT3A mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a WNT1, WNT2, or WNT3A gene in a cell or in a subject to treat a WNT1, WNT2, or WNT3A-related disease.03-04-2010
20100055782NUCLEIC ACID COMPOUNDS FOR INHIBITING MYC GENE EXPRESSION AND USES THEREOF - The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing MYC gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-over-lapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a MYC mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a MYC gene in a cell or in a subject to treat a MYC-related disease.03-04-2010
20100055781SUBSTRATE FOR CULTURE OF CARDIOVASCULAR TISSUE - The scaffold for culturing a cardiovascular tissue of the present invention is a scaffold for culturing a cardiovascular tissue, which is tubular, and comprises a foamed polymer comprising a bioabsorbable material reinforced with a reinforcing material comprising a bioabsorbable material, the foamed polymer comprising lactide (D, L, DL isomer)-ε-caprolactone copolymer containing lactide (D, L, DL isomer) in a content of 50 to 54 mole % and ε-caprolactone in a content of 50 to 46 mole %, and the reinforcing material being covered with the foamed polymer.03-04-2010
20100055785ENDOGENOUS EXPRESSION OF HLA-G AND/OR HLA-E BY MESENCHYMAL CELLS - Methods and compositions are provided for the identification and isolation of mammalian HLA-G03-04-2010
20110081719Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same - Methods for producing substantially pure cultures of human neural retinal progenitor cells, forebrain progenitor cells, and retinal pigment epithelial cells are disclosed. In addition, the successful differentiation of human embryonic stem cells and human induced pluripotent stem cells through the major developmental stages of human retinogenesis is disclosed.04-07-2011
20110081720METHOD OF DIFFERENTIATING STEM CELLS INTO CELLS OF THE ENDODERM AND PANCREATIC LINEAGE - Methods are described to more efficiently produce cells of the endoderm and pancreatic lineage from mammalian pluripotent stem cells. These methods provide a simple, reproducible culture protocol using defined media components to enable consistent, large-scale production of pancreatic cell types for research or therapeutic uses.04-07-2011
20110076764METHODS AND KITS FOR CELL RELEASE - Methods and kits of releasing cells are provided. The method comprises the steps of providing cultured cells on a cell culture support comprising a multi layer polyelectrolyte coating immobilized on a substrate, and releasing the cultured cells from the cell culture support by a releasing solution comprising DMSO. The kit comprises a cell culture support and a releasing solution. The releasing solution comprises DMSO.03-31-2011
20120202288COMPOSITIONS COMPRISING CYCLIC AMP ENHANCERS AND/OR EP LIGANDS, AND METHODS OF PREPARING AND USING THE SAME - Provided are improved pharmaceutical compositions that comprise ligands or agonists to prostaglandin EP receptors, and/or cyclic AMP enhancers, and suitable organic solvents that are substantially free of methyl acetate, the compositions being provided for storage and/or use in an endotoxin-free vessel, such as a tube or PE bag. The compositions are suitable for in vitro, ex vivo, and in vivo use, and in particular for ex vivo therapeutic use, such as in hematopoietic stem cell transplants. Also provided are methods of using the compositions in ex vivo therapeutic applications, and methods of preparing the compositions. Kits with instructions on use are also provided.08-09-2012
20120202287Stem Cell Culture Methods - The invention provides methods for reversibly inhibiting stem cell differentiation wherein a compound of formula (I) is contacted with a stem cell. The invention further provides a method for preparing a culture medium, a culture medium supplement and a composition comprising a compound of formula (I).08-09-2012
20110008885LINEAR DOUBLE-STRANDED RNA MOLECULE INTERFERING WITH DIFFERENT TARGET GENES - A linear double-stranded RNA molecule, which comprises two or more consecutively or convergently linked short interfering RNAs (siRNAs) each reducing the expression of one of different target genes, and a recombinant expression vector comprising double-stranded DNA sequence expressing the linear double-stranded RNA molecule are provided. The linear double-stranded RNA molecule or the recombinant expression vector is useful for a method of reducing expression of target genes in a cell, the method comprising introducing the linear double-stranded RNA molecule or the recombinant expression vector into the cell, whereby the encoded siRNAs target different genes and reduce expression of the target genes. It was also proved that effective gene silencing activity can be induced when each siRNA unit within the linear double-stranded RNA molecule has 18 to 24 nucleotides and, additionally, the gene silencing activity is not affected by inverted orientation of an siRNA.01-13-2011
20110256623Primate Embryonic Stem Cells - A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (−); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a particularly advantageous embodiment, the cells of the preparation are human embryonic stem cells, have normal karyotypes, and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed.10-20-2011
20100297757RENAL PROGENITOR CELLS FROM EMBRYONIC STEM CELLS - The present invention relates to compositions and methods for inducing the differentiation of stem cells into renal progenitor cells. In particular, the present invention provides compositions containing activin-a, retinoic acid, and bmp-7, and variants thereof, for differentiating stem cells into renal cells containing tubular epithelia. In certain embodiments, the present invention provides stem cells cultured with compositions used to treat renal disease.11-25-2010
20110177593LOW RIGIDITY GELS FOR MSC GROWTH MODULATION - This invention provides gels and matrices having a rigidity in the range of 0.1-2.5 kPa, methods of manufacturing same, and method of preserving a mesenchymal stem cell population or studying mesenchymal stem cells, comprising same.07-21-2011
20110177594STEM CELLS CULTURE SYSTEMS - Provided are systems and methods for providing human cell cultures. Further provided are cultures of feeder cells for use in stem cell technology, as well as cultures, culture systems and methods for maintenance and propagating of stem cells in an undifferentiated state as well as for the development of somatic cells cultures from stem cells, the somatic cell cultures being free of extraembryonic cells.07-21-2011
20090029464Feeder Independent Extended Culture of Embryonic Stem Cells - Previous methods for culturing human embryonic stem cells have required either fibroblast feeder cells or a medium which has been exposed to fibroblast feeder cells in order to maintain the stem cells in an undifferentiated state. It has now been found that if an antagonist of bone morphogenic protein is added to the medium in which the stem cells are cultured, together with fibroblast growth factor, the stem cells will remain undifferentiated indefinitely, even without feeder cells or conditioned medium.01-29-2009
20090029463Differentiation of Multi-Lineage Progenitor Cells to Chondrocytes - Fetal blood multi-lineage progenitor cells that are capable of a wide spectrum of transdifferentiation are described, as well as methods of differentiating the progenitor cells into chondrocytes.01-29-2009
20090029462AUTOMATED METHOD AND APPARATUS FOR EMBRYONIC STEM CELL CULTURE - The invention concerns methods for automated culture of embryonic stem cells (ESCs) such as human ESCs. In some aspects, methods of the invention employ optimized culture media and limited proteolytic treatment of cells to separate cell clusters for expansion. Automated systems for passage and expansion of ESCs are also provided.01-29-2009
20120276626SYNTHETIC SURFACES FOR CULTURING STEM CELL DERIVED CARDIOMYOCYTES - Synthetic surfaces suitable for culturing stem cell derived cardiomyocytes contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived cardiomyocytes in chemically defined media.11-01-2012
20120276625METHOD FOR PRODUCING MESENCHYMAL STEM CELLS FROM HUMAN PLURIPOTENT STEM CELLS, AND MESENCHYMAL STEM CELLS PRODUCED BY SAME - Provided is a method for producing mesenchymal stem cells from human pluripotent stem cells, the method including: a) forming embryonic bodies from human pluripotent stem cells; b) attaching the embryonic bodies to a culture dish to induce natural differentiation of the embryonic bodies into mesenchymal stem cells; and c) performing continuous proliferative culturing of the mesenchymal stem cells while still maintaining the identity of the mesenchymal stem cells. Also, provided is a standardized method for inducing differentiation of mesenchymal stem cells, which can be broadly applied to all human pluripotent stem cells regardless of a difference in the genetic background thereof. Ultimately, the present invention can continuously mass-produces the mesenchymal stem cells necessary for regenerative medicine and cell therapy by using human pluripotent stem cells, thereby realizing practical uses of cell therapy products, and further the present invention is expected to highly contribute to treatments of incurable diseases, such as cardiovascular diseases and neurological disorders.11-01-2012
20080286863METHOD AND SOLUTIONS FOR CRYOPRESERVING OOCYTES, ESPECIALLY FRESH HUMAN OOCYTES - In a method for cryopreserving fresh human oocytes, freezing and thawing solutions are used, which solutions include 11-20-2008
20080206864Methods and Materials for Culturing Murine Embryonic Stem Cells - This disclosure provides methods for culturing murine ES cells in an undifferentiated state using human foreskin fibroblasts (HFF) feeder layer cells in the absence of exogenous Leukemia Inhibitory Factor (LIF).08-28-2008
20110027880CELL CULTURE SYSTEM FOR PANCREATIC ISLANDS - Three-dimensional (3D) insulin-producing cell clusters derived from stem cells (preferably human embryonic stem cells) are provided by this invention, together with a method for their production using a microgravity bioreactor cell culture system.02-03-2011
20110256624BIOREACTOR - The invention relates to a bioreactor, to the use of the bioreactor for culturing microorganisms or cell cultures, and also to a method for culturing microorganisms or cell cultures.10-20-2011
20100285581Solid Phase Cell Isolation and/or Enrichment Method - The present invention concerns a solid phase method for isolating and/or enriching predetermined cells from a sample. Such methods are used e.g. to isolate and enrich predetermined cells like fetal cells from a sample of maternal peripheral blood, tumor cells from a sample of body fluid or stem cells from a fluid or fluidized sample of body tissue or body fluid. The solid phase isolation method of the present invention is used for isolating predetermined cells from a sample containing such predetermined cells by binding the predetermined cells to a solid surface. According to the invention the sample is contacted with the solid surface and then removed from the solid surface, wherein the sample or a washing buffer contains a polyol during or after contacting the sample with the solid surface.11-11-2010
20090093054CRYOPRESERVATION OF HUMAN BLASTOCYST-DERIVED STEM CELLS BY USE OF A CLOSED STRAW VITRIFICATION METHOD - An improved method for vitrification of biological cells, especially blastocyst-derived stem cells (BS cells). The method is very mild for the cells that remain viable after they have been thawed. The method comprises, i) transfer of the cells to a first solution (solution A), ii) optionally incubation of the cells in the first solution, iii) transfer the cells obtained in step i) or ii) to a second solution (solution B), iv) optionally incubation of the cells in the second solution, v) transfer of the cells obtained from step iii) or iv) into one or more closed straws with dimensions that allow a volume of at least 20 μl to be contained in them vi) sealing the one or more closed straws, and vii) vitrification of the one or more closed straws. An important feature of the present invention is the use of closed straw and that relatively large volumes can be efficiently vitrified and subsequently thawed.04-09-2009
20120178160Cultivation Of Primate Embryonic Stem Cells - The invention relates to methods for culturing human embryonic stem cells by culturing the stem cells in an environment essentially free of mammalian fetal serum and in a stem cell culture medium including amino acids, vitamins, salts, minerals, transferrin, insulin, albumin, and a fibroblast growth factor that is supplied from a source other than just a feeder layer the medium. Also disclosed are compositions capable of supporting the culture and proliferation of human embryonic stem cells without the need for feeder cells or for exposure of the medium to feeder cells.07-12-2012
20120178159MESENCHYMAL STEM CELLS (MSC) EXPANSION METHODS AND MATERIALS - The subject invention concerns materials and methods for growing and expanding MSC while maintaining their undifferentiated phenotype, self-renewal ability, and/or multi-lineage potential. In one embodiment, a method of the invention comprises i) seeding freshly isolated MSC on a planar surface or a 3-D scaffold and growing the cells under physiological or low O07-12-2012
20090176304Method for in vivo, ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling - A method for in vivo, ex vivo and in vitro regeneration of cartilage and collagen. In vivo, ex vivo and in vitro regeneration and de novo formation of articular cartilage and collagen by intermittently applied hydrostatic pressure. The application of external interval loading consisting of repeated periods of applied hydrostatic pressure followed and interrupted by periods of recovery. The application of the intermittent hydrostatic pressure at physiological levels 5-10 MPA for an interval of 07-09-2009
20100190249METHOD AND DEVICE FOR FORMING A THREE-DIMENSIONAL ARRANGEMENT OF BIOLOGICAL CELLS - A method for forming a three-dimensional cell arrangement (07-29-2010
20110189768Mesenchymal Stem Cells Expressing TNF-alpha Receptors - Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/1008-04-2011
20110263015COMPOSITIONS AND METHODS FOR GENERATION OF PLURIPOTENT STEM CELLS - The present invention describes the use of pre-trans-splicing molecules (PTMs) to reprogram human normal and diseased somatic cells into pluripotent stem cells using spliceosome-mediated RNA trans-splicing. More specifically, the present invention describes the use of the SMaRT™ technology to repair or reprogram the newly induced diseased pluripotent stem cells.10-27-2011
20110263014Cleavage of Nanog by Caspases Mediates the Differentiation of Embryonic Stem Cells - The present invention is based on the discovery that a caspase specifically cleaves the transcription factor, Nanog, leading to the initiation of cellular differentiation of embryonic stem (ES) cells. The present invention includes a method of inhibiting the cleavage of Nanog, thereby maintaining the pluripotency of an ES cell or preventing the differentiation of an ES cell. The present invention further provides compositions and methods for inhibiting caspase expression, activity, and/or stability.10-27-2011
20100021998DEFINED CELL CULTURING SURFACES AND METHODS OF USE - In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.01-28-2010
20090191625siRNA targeting connective tissue growth factor (CTGF) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF.07-30-2009
20100068806NOVEL METHODS AND REAGENTS DIRECTED TO PRODUCTION OF CELLS - The present invention provides methods and materials to modulate and grow stem cells by contacting stem cells with a binder recognizing terminal glycan structures of stem cells. The modulation can be morphological change, change in differentiation status, biological status or adherence. The materials provided in the present invention are also useful to screen such a binding agents and binders.03-18-2010
20120231542Biologically Active Human Umbilical Cord Blood Cell Extract Compounds and Methods - Compositions and methods for culturing therapeutic cells are provided herein. According to at least one embodiment, compositions comprising cord blood plasma and lysed platelets and methods for making and using same are provided herein.09-13-2012
20090104695Stem Cells Culture Systems - The present invention concerns systems and methods for providing human cell cultures. Specific embodiments of the invention relate to cultures of feeder cells for use in stem cell technology, as well as cultures, culture systems and methods for maintenance and propagating of stem cells in an undifferentiated state as well as for the development of somatic cells cultures from stem cells, the somatic cell cultures being free of extraembryonic cells.04-23-2009
20100297758ARTIFICIAL PEPTIDE AND USE THEREOF - The present invention provides a method of transporting a peptide motif of interest into a nucleus of a eukaryotic cell from outside the cell, including: synthesizing a peptide chain having an amino acid sequence constituting the peptide motif of interest at an N-terminal end or a C-terminal end of a cell membrane-permeable nucleolar localization signal sequence defined by the amino acid sequence KKRTLRKNDRKKR (SEQ ID NO: 1); adding the synthesized peptide to a culture medium which includes the eukaryotic cell or a tissue containing the eukaryotic cell; and culturing the eukaryotic cell to which the synthesized peptide is added, or the tissue containing the cell.11-25-2010
20110312090CARDIOMYOCYTE MEDIUM WITH DIALYZED SERUM - Methods and composition for maintenance of cardiomyocytes are provided. For example, in certain aspects methods including culturing the cardiomyocytes in a medium essentially free of serum or containing dialyzed serum to maintain long-term purity. In further aspects, methods for modulation of cardiomyocytes may be provided.12-22-2011
20100021999Methods of preparing feeder cells-free, xeno-free human embryonic stem cells and stem cell cultures prepared using same - The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.01-28-2010
20110306129STEM CELL GROWTH MEDIA AND METHODS OF MAKING AND USING SAME - The invention provides media formulations. A complete media formulation of the invention includes, for example, the following components: albumin, an iron carrier, glutamine, a glycosidase or hydrolase, fibroblast growth factor (FGF), a salt or mineral, and essential amino acids at an osmolarity of about 220-330 mOsm/Liter.12-15-2011
20110306131INDUCTION OF PLURIPOTENT STEM CELLS INTO MESODERMAL LINEAGES - The present invention provides a method of inducing mesoderm derived cells from pluripotent stem cells. In contrast to methods known in the art that are often designed to replicate in vivo events of mesoderm induction, the present invention provides a unique, yet simple, method whereby pluripotent stem cells are mesodermally primed in the presence of factors that concomitantly inhibit the spontaneous differentiation of endoderm and ectoderm during expansion and suspension steps. Exposure and/or adherence of primed aggregates to a extracellular matrix that promotes the commitment and survival of induced mesoderm progenitors, followed by exposure to various mesoderm associated factors, allows for the subsequent induction of such cells into terminally differentiated lineages, such as cardiomyocytes. End products of this induction system will ultimately provide an unlimited source of mesoderm-derived cell types for therapeutic and pharmacological purposes.12-15-2011
20110306130INDUCTION OF PLURIPOTENT STEM CELLS INTO MESODERMAL LINEAGES - The present invention provides a method of inducing mesoderm derived cells from pluripotent stem cells. In contrast to methods known in the art that are often designed to replicate in vivo events of mesoderm induction, the present invention provides a unique, yet simple, method whereby pluripotent stem cells are mesodermally primed in the presence of factors that concomitantly inhibit the spontaneous differentiation of endoderm and ectoderm during expansion and suspension steps. Exposure and/or adherence of primed aggregates to a extracellular matrix that promotes the commitment and survival of induced mesoderm progenitors, followed by exposure to various mesoderm associated factors, allows for the subsequent induction of such cells into terminally differentiated lineages, such as cardiomyocytes. End products of this induction system will ultimately provide an unlimited source of mesoderm-derived cell types for therapeutic and pharmacological purposes.12-15-2011
20110306128CULTURE OF CELLS - The invention relates to a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) cells on a lectin. The invention relates also to the use of a lectin in a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) celts and a culture medium composition containing a lectin attached on the culturing plates.12-15-2011
20090325289PROCESS FOR THE MULTIPLICATION OF STEM CELLS - The use of a cellular development inhibitor in a controlled manner in order to maintain an undifferentiated stem cell state, especially one of human stem cells, whereby cell division is permitted.12-31-2009
20090023207CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS - Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.01-22-2009
20110111496BACTERIA-MEDIATED GENE MODULATION VIA microRNA MACHINERY - The present invention provides a method of synthesizing, processing, and/or delivering miRNA or its precursors to eukaryotic cells using bacteria, preferably non-pathogenic or therapeutic strains of bacteria, to effect gene modulation in eukaryotic cells.05-12-2011
20100197013METHOD FOR CULTURING STEM CELLS - A three-dimensional microwell system that supports long term pluripotent cell culture and formation of homogeneous embryoid bodies (EBs) is described. Microwell-cultured pluripotent cells remain viable and undifferentiated for several weeks in culture and maintain undifferentiated replication when passaged to Matrigel®-coated, tissue culture-treated polystyrene dishes. Microwell-cultured pluripotent cells maintain pluripotency, differentiating to each of the three embryonic germ layers. Pluripotent cell aggregates released from microwells can be passaged for undifferentiated replication or differentiated to monodisperse EBs. The ability to constrain pluripotent cell growth in three dimensions advantageously provides for more efficient, reproducible culture of undifferentiated cells, high-throughput screening, and the ability to direct pluripotent cell differentiation by generating monodisperse EBs of a desired size and shape. Cardiomyocyte-rich EBs are obtained from pluripotent cells cultured in microwells of defined size and shape.08-05-2010
20110318833ADIPOSE-DERIVED STEM CELLS AND LATICCES - The present invention provides adipose-derived stem cells and lattices. In one aspect, the present invention provides a lipo-derived stem cell substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The cells can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the cells can be expanded and cultured to produce hormones and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a lipo-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.12-29-2011
20110318832Human Telomerase Catalytic Subunit - The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.12-29-2011
20100267135MULTIPOTENT/PLURIPOTENT CELLS AND METHODS - Described herein are multipotent stem cells, e.g., human and other mammalian pluripotent stem cells, and related methods.10-21-2010
20120045830STEM CELL AGGREGATE SUSPENSION COMPOSITIONS AND METHODS OF DIFFERENTIATION THEREOF - The present invention relates to methods for production of undifferentiated or differentiated embryonic stem cell aggregate suspension cultures from undifferentiated or differentiated embryonic stem cell single cell suspensions and methods of differentiation thereof.02-23-2012
20100210013POSTPARTUM CELLS DERIVED FROM UMBILICAL CORD TISSUE, AND METHODS OF MAKING AND USING THE SAME - Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.08-19-2010
20120003736METHODS FOR CULTURING UNDIFFERENTIATED CELLS USING SUSTAINED RELEASE COMPOSITIONS - Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state.01-05-2012
20090111177Maintenance of Embryonic Stem Cells by the GSK-3 Inhibitor 6-Bromoindirubin-3'-Oxime - The present invention relates to methods for maintaining the undifferentiated state of embryonic stem cells without the use of a feeder layer by activating the Wnt signal transduction pathway or by inhibiting glycogen synthase kinase-3 activity by contacting the cell with, inter alia, 6-bromoindirubin-3′-oxime. The present invention also relates to embryonic stem cell lines and cells derived therefrom that have been isolated and cultured in the absence of a feeder layer.04-30-2009
20120208273VESSEL FOR CULTURING CELLS - The present invention provides an apparatus for culturing cells which may comprise two or more culture compartments and a pooling compartment, wherein each of said two or more culture compartments may be separated from the other culture compartments; each of said two or more culture compartments which may comprise a port for the addition or removal of medium; and the pooling compartment communicates with said two or more culture compartments. The present invention also relates to a stand for apparatus for culturing cells.08-16-2012
20120009674Use of a GSK-3 Inhibitor to Maintain Potency of Cultured Cells - The present invention is directed to the culture of non-embryonic cells, that can differentiate into cell types of more than one embryonic lineage, in culture under conditions that maintain differentiation capacity during expansion; more particularly, culturing non-embryonic cells in the presence of at least one GKS-3 inhibitor, such as BIO.01-12-2012
20120009675METHODS OF PRODUCING PANCREATIC HORMONES - Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.01-12-2012
20120009673MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CNS DISEASES - An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.01-12-2012
20120015439METHOD FOR THE RECONSTRUCTION OF A TISSUE-ENGINEERED HUMAN CORNEAL ENDOTHELIUM - This invention relates to a method for the reconstruction of a tissue-engineered human corneal endothelium. Human corneal endothelial cells are cultured in vitro to logarithmic growth phase using 20% calf bovine serum-containing DMEM/F12 medium. Trypsin is used to digest epithelial layer of the freeze-dried human amniotic membrane in order to produce denuded human amniotic membrane as scaffold carriers. The scaffold carriers are tiled on the bottom of culture plate wells until they are dried and completely adhered to the bottom of wells. Human corneal endothelial cells at logarithmic growth phase are re-suspended in DMEM/F12 medium containing type-IV collagen and 20% calf bovine serum. Human corneal endothelial cell suspension is subsequently inoculated to amniotic membrane scaffold carriers that are tiled on the bottom of wells in culture plate to launch in vitro culture as well as in vitro reconstruction of tissue-engineered human corneal endothelium. This invention is scientific and rational. The reconstructed tissue-engineered human corneal endothelium can be produced on large scale to satisfy the great demand of tissue-engineered human corneal endothelium in clinical cornea transplantation for primary corneal endotheliopathy therapy. Meanwhile, costs for in vitro reconstruction of tissue-engineered human corneal endothelium and clinical therapy are low.01-19-2012
20090035851Modulators Of NOD1 Signaling - The present invention relates to intracellular signaling molecules, in particular the Nod1 protein. The present invention provides methods of identifying modulators of Nod1 signaling. The present invention further provides methods of altering Nod1 signaling.02-05-2009
20120156777CELL CARRIER, ASSOCIATED METHODS FOR MAKING CELL CARRIER AND CULTURING CELLS USING THE SAME - A carrier for growing adherent cells is provided, wherein the carrier comprises one or more outer surfaces; and one or more structured indentations on one or more of the outer surfaces, wherein the carrier has a length at least about 0.2 mm, a width at least about 0.2 mm, and a height in a range from about 0.05 mm to 1.2 mm and each of the structured indentations has a major axis in a range from about 0.1 mm to 0.5 mm, a minor axis in a range from about 0.1 mm to 0.5 mm and a depth in a range from about 0.025 mm to about 0.5 mm. The carrier may comprise a single indentation or ‘cup’ like structure, or may comprise a plurality of indentations. A method of making the carrier, and culturing stromal cells using the same carrier are also provided.06-21-2012
20110039332HUMAN PLURIPOTENT STEM CELLS INDUCED FROM UNDIFFERENTIATED STEM CELLS DERIVED FROM A HUMAN POSTNATAL TISSUE - To establish human pluripotent stem cells having properties close to human ES cells comprising the genome of the patient per se that can circumvent immunological rejection of transplanted cells from cells derived from a postnatal human tissue. It was found that human pluripotent stem cells can be induced by introducing three genes of Oct3/4, Sox2 and KIf 4, or three genes of Oct3/4, Sox2 and KIf 4 plus the c-Myc gene or a histone deacetylase (HDAC) inhibitor to undifferentiated stem cells present in various human postnatal tissues in which each gene of Tert, Nanog, Oct3/4 and Sox2 has not undergone epigenetic inactivation.02-17-2011
20100093083LARGE SCALE PRODUCTION OF STEM CELLS - Methods for large-scale production of stem cells, including embryonic stem cells, are provided. Also provided are methods for large-scale production of differentiated cells derived from stem cells and use of stem cells or the differentiated progeny thereof in assays.04-15-2010
20100093082Site Specific Incorporation of Non-Natural Amino Acids by Vertebrate Cells - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in vertebrate cells. The components include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNA's/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in vertebrate cells are also provided.04-15-2010
20120122210CARRIER PEPTIDE FRAGMENT AND USE THEREOF - A method for transferring a foreign substance includes the steps of: preparing a construct for transferring a foreign substance that contains a carrier peptide fragment including either the amino acid sequence KKRTLRKNDRKKR (SEQ ID NO. 1) or an amino acid sequence formed by the substitution, deletion, and/or addition (insertion) of 1, 2, or 3 amino acid residues in the amino acid sequence, and a foreign substance of interest that is bonded to the N-terminus and/or C-terminus of the carrier peptide fragment; supplying the construct for transferring a foreign substance to a test sample that contains a target eukaryotic cell; and incubating the test sample that has been supplied with the construct for transferring a foreign substance to thereby transfer the construct into the eukaryotic cell in the test sample.05-17-2012
20120122209Undifferentiated Stem Cell Culture Systems - The present disclosure provides methods for maintaining and propagating undifferentiated pluripotent stem cells (SC) in suspension. The methods comprise culturing such SC in a non-adherent culture dish under conditions comprising a basic serum free medium and one or more of a basic medium, a serum replacement, an extra cellular matrix component and a factor supporting expansion of said SC. A specific and preferred culture condition comprise supplementing Neurobasal™ medium with KO serum replacement (KOSR). These conditions allowed for large scale and long term propagation of undifferentiated pluripotent SC. The culture system comprising suspended undifferentiated pluripotent SC were found to have many applications including in methods for directed as well as spontaneous differentiation of the SC into somatic cells. Also disclosed herein is a method of deriving SC, preferably human embryonic SC from human embryos via the formation of cell clusters.05-17-2012
20120122208Tubular Bioreactor System for Use in Bone and Cartilage Tissue Engineering - A bioreactor system includes a growth chamber having an inlet, an outlet, and defining a cavity, a media reservoir is in fluid communication with the inlet, and a pump configured to perfuse a media from the reservoir into the inlet and through the growth chamber. A plurality of discrete scaffold members is packed within the growth cavity. Spaces between adjacent scaffold members define pores. The media is movable around the scaffold members and through the pores via the pump.05-17-2012
20090263896METHODS FOR PURIFYING ENDODERM AND PANCREATIC ENDODERM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS - The present disclosure relates to compositions and methods comprising cell surface markers for hES-derived cells, in particular, endoderm lineage cells including pancreatic endoderm-type cells, derived from hES cells.10-22-2009
20110183415DERIVATION OF EMBRYONIC STEM CELLS AND EMBRYO-DERIVED CELLS - This present invention provides novel methods for deriving embryonic stem cells and embryo-derived cells from an embryo without requiring destruction of the embryo. The invention further provides cells and cell lines derived without embryo destruction, and the use of the cells for therapeutic and research purposes. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.07-28-2011
20100210014Nuclear reprogramming factor and induced pluripotent stem cells - The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including screening and testing methods as well as methods of stem cell therapy. The present invention also relates to somatic cells derived by inducing differentiation of the aforementioned iPS cells.08-19-2010
20120171767COMPOSITIONS AND METHODS FOR GROWING HUMAN EMBRYONIC CELLS - Methods for deriving and cultivating human embryonic stem (ES) cells and maintaining their pluripotency in culture is provided by utilizing secreted products obtained from the culture medium of human embryonic gem (EG) cell derivatives, such as embryoid body-derived cells. Substrates include compounds such as collagen I, fibronectin, or superfibronectin, or extracellular matrix, typically human derived.07-05-2012
20120171766MEDIUM COMPOSITION COMPRISING NEUROPEPTIDE Y FOR THE GENERATION, MAINTENANCE, PROLONGED UNDIFFERENTIATED GROWTH OF PLURIPOTENT STEM CELLS AND METHOD OF CULTURING PLURIPOTENT STEM CELL USING THE SAME - The present invention relates to a medium composition comprising neuropeptide Y, effective for proliferation and maintenance of undifferentiated pluripotent stem cells, and a method for culturing undifferentiated pluripotent stem cells using the same. The present invention improves the culture conditions for undifferentiated pluripotent stem cells, and ultimately, the present invention can be effectively used for the development of large-scale culture systems, thereby acquiring clinically applicable pluripotent stem cells. Further, the present invention relates to a dedifferentiation medium composition comprising neuropeptide Y (NPY), and a method for inducing dedifferentiation (or reprogramming) using the same. The present invention improves the culture conditions for dedifferentiation and contributes to develop technology of producing clinically applicable induced pluripotent stem cells, thereby being used for the development of stem cell therapy.07-05-2012
20120315699STACKED, PATTERNED BIOMATERIALS AND/OR TISSUE ENGINEERING SCAFFOLDS - Stacked, lamellar constructs comprised of, synthetic or natural, polymeric membrane structures which are brought together to form 3D scaffolds for biomaterial and guided tissue engineering applications have been developed. Each layer can have 2D or 3D nano and micro topographical features similar to or different than each other which can be arranged during the construction of each lamellae and their orientation can be adjusted during construction phase of the 3D structure. Such a construct was utilized in the development of an artificial cornea with human primary cells, in which patterned surface of the components of the lamellar structure mimics the oriented collagen structure inherent in natural cornea. Similar exploitation of the 3D patterned structure can be made for tissues where aligned ECM architecture is crucial, such as ligaments, bone, tendon, skin.12-13-2012
20120315698METHODS FOR STERILIZING MATERIALS CONTAINING BIOLOGICALLY ACTIVE AGENTS - Provided are methods for sterilizing a material comprising a biologically-active agent comprising irradiating said material with ionizing radiation at a dose of about 5 kGy to about 25 kGy while maintaining said material in an atmosphere comprising at least 95% by volume inert gas and at a temperature of about 4° C. or lower. Also provided are sterilized materials comprising a biologically-active agent, wherein said materials exhibit substantially the same amount of biological activity as a non-sterilized control.12-13-2012
20090275129TISSUE ENGINEERED BLOOD VESSELS - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed.11-05-2009
20120135519INDUCED DERIVATION OF SPECIFIC ENDODERM FROM hPS CELL-DERIVED DEFINITIVE ENDODERM - The present invention relates to a method to control differentiation of human pluripotent stem cells, including human balstocyst derived stem (hBS) cells and to obtain specific endoderm cells. In particular, present invention relates to the use of FGF2 as the key factor in a specific concentration to control differentiation of definitive endoderm cells derived from hPS cells to specific endoderm cells. The invention also provides methods of obtaining endoderm cells comprising the use of FGFR and activation of the MAPK signalling pathway.05-31-2012
20120135518DEFINED SURFACES OF SELF-ASSEMBLED MONOLAYERS AND STEM CELLS - A method for the construction of arrays from self-assembling monolayers is described. The arrays have particular utility for the screening of peptides ligands that can foster the growth of cells in culture. This technique has been used to identify peptide ligands that foster the growth of human stem cells, which otherwise require an extracellular matrix in order to grow in an undifferentiated state. This also makes possible an assay to identify other such peptides.05-31-2012
20120220031CULTURE SUBSTRATE FOR HUMAN PLURIPOTENT STEM CELLS AND USE THEREOF - The present invention provides a culture substrate which enables maintenance culture of human pluripotent stem cells in a pluripotent state under a feeder-free culture environment, and a culture method of human pluripotent stem cells using the culture substrate. By seeding human pluripotent stem cells dissociated into single cells at a cell density of 4×1008-30-2012
20120220030Enhanced Efficiency of Induced Pluripotent Stem Cell Generation from Human Somatic Cells - A substantially pure population of human somatic cells that have enhanced potential to become induced pluripotent stem cells (iPS cells) is provided. Also provided are methods for generating this population of cells and methods for generating iPS cells from this population of cells.08-30-2012
20120135520UNSHRUNKEN TISSUE EQUIVALENT, SKIN EQUIVALENT COMPRISING SUCH AN UNSHRUNKEN TISSUE EQUIVALENT, AND METHODS FOR PRODUCING SUCH AN UNSHRUNKEN TISSUE EQUIVALENT AND SUCH A SKIN EQUIVALENT - The invention relates to a method for producing an unshrunken tissue equivalent. Said method is comprising in that: a mixture is produced that contains at least one element of an extracellular matrix; at least one pluridimensional medium is soaked with said mixture; from the components of the mixture, a lattice comprising at least one element of an extracellular matrix is produced, at least at the medium; at least part of the components of said mixture is attached to the structure of the medium; the shrinking of at least the lattice is prevented and at least said lattice is tensioned on said medium; fibroblasts are integrated into the lattice and at least one cell culture of said fibroblasts is carried out, at least in the lattice. The invention also relates to a method for producing a skin equivalent that comprises at least one dermal equivalent formed by an unshrunken tissue equivalent and at least one epidermal equivalent.05-31-2012
20100173410Cultivation of Primate Embryonic Stem Cells - The invention relates to methods for culturing human embryonic stem cells by culturing the stem cells in an environment essentially free of mammalian fetal serum and in a stem cell culture medium including amino acids, vitamins, salts, minerals, transferrin, insulin, albumin, and a fibroblast growth factor that is supplied from a source other than just a feeder layer the medium. Also disclosed are compositions capable of supporting the culture and proliferation of human embryonic stem cells without the need for feeder cells or for exposure of the medium to feeder cells.07-08-2010
20100173411Adipose-derived stem cells and lattices - The present invention provides adipose-derived stem cells and lattices. In one aspect, the present invention provides a lipo-derived stem cell substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The cells can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the cells can be expanded and cultured to produce hormones and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a lipo-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.07-08-2010
20120214232METHODS OF CULTURING CELLS IN A MEDIUM COMPRISING TRANSFORMING GROWTH FACTOR BETA 1 AND BASIC FIBROBLAST GROWTH FACTOR - The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.08-23-2012
20120178161MEDIUM AND CULTURE OF EMBRYONIC STEM CELLS - Previous methods for culturing primate pluripotent stem cells have required either fibroblast feeder cells or a medium which was exposed to fibroblast feeder cells to maintain the stem cells in an undifferentiated state. It has now been found that high levels of fibroblast growth factor in a medium together with at least one of gamma aminobutyric acid, pipecolic acid, and lithium, enables pluripotent stem cells to remain undifferentiated indefinitely through multiple passages, even without feeder cells or conditioned medium. Without beta-mercaptoethanol, the medium improves cloning efficiency. Also, a matrix of human proteins can be used to culture the undifferentiated cells without exposing the cells to animal products. Further disclosed are new primate pluripotent cell lines made using the defined culture conditions, including the medium and the matrix. Such new cell lines will have never been exposed to animal cells, animal products, feeder cells or conditioned medium.07-12-2012
20090061513Cell sorting and cell cultivation methods - A method of cell seeding is provided, which comprises the steps of: 03-05-2009
20090061512CULTURE MEDIUM FOR GINGIVAL FIBROBLASTS - The present invention relates to a gingival fibroblast culture medium free of animal serum, comprising an animal cell culture medium, free of animal serum, to which is added: 03-05-2009
20120225480CULTURE MEDIA, CELL CULTURES AND METHODS OF CULTURING PLURIPOTENT STEM CELLS IN AN UNDIFFERENTIATED STATE - Provided are serum-free culture media which comprise basic fibroblast growth factor (bFGF), transforming growth factor beta-3, ascorbic acid, xeno-free serum replacement and a lipid mixture. The media may also comprise an IL6R/IL6 chimera, or leukemia inhibitory factor (LIF); wherein the culture medium is capable of maintaining pluripotent stem cells in an undifferentiated state in the absence of feeder cell support. Also provided are cell cultures comprising pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem (iPS) cells, and methods of using the same for expanding pluripotent stem cells in an undifferentiated state using two-dimensional or three-dimensional culture systems. Methods of expanding iPS cells in a suspension culture devoid of substrate adherence and cell encapsulation are also provided.09-06-2012
20100144032PROCESS FOR ISOLATING VASCULAR ENDOTHELIAL CELLS FROM EMBRYOID BODIES DIFFERENTIATED FROM EMBRYONC STEM CELLS - The present invention provides a process for isolating vascular endothelial cells from embryoid bodies differentiated from embryonic stem cells, which comprises: (a) treating embryoid bodies differentiated from embryonic stem cells with 0.005-0.015% trypsin and 0.05-0.15 mM ethylenediaminetetraacetate (EDTA) to obtain vascular endothelial cell clusters; and (b) treating the vascular endothelial cell clusters with 0.1-0.5% trypsin and 0.5-2 mM EDTA so as to separate the vascular endothelial cell clusters into single cells.06-10-2010
20120282691EXTRACELLULAR MATRIX COATED SURFACE FOR CULTURING CELLS - A cell culture product is provided for propagating embryonic stem cells, and maintaining their self-renewal and pluripotency characteristics for extended periods of time in culture. The cell culturing product includes a substrate; and a coating thereon deposited from a coating solution. The coating solution includes a mixture of extracellular matrix proteins and an aqueous solvent, wherein the total protein concentration in the coating solution is about 10 μg/m1 to about 1 mg/ml.11-08-2012
20080299654Methods of inhibiting smooth muscle cell migration and proliferation - In particular embodiments, the present invention provides methods of inhibiting smooth muscle cell responses and methods of treating or preventing vascular proliferative disease caused by smooth muscle cell migration and proliferation. More specifically, smooth muscle cell responses are inhibited by introducing an agent into smooth muscle cells, wherein the agent inhibits an activity of one or more members of the myristoylated alanine-rich C kinase substrate (MARCKS) family of proteins. The invention also provides methods of inhibiting expression of one or more genes encoding a member of the MARCKS family of proteins in a cell.12-04-2008
20120264210Method for Expanding and/or Preserving Cells by Means of Gas Enrichment of the Culture Medium - A method for expanding and/or preserving cells inside a culture vessel containing a culture medium provides for the renewal of the culture medium by a culture medium stream, at least a portion of which comes from a culture medium volume contained in a gas-enrichment vessel of the culture medium, the enrichment-vessel further containing a gas volume which is separated from the culture medium volume by a free interface, the gas volume being renewed by a gas stream that is introduced into the enrichment vessel directly into the gas volume, the flow of the stream being arranged so as to enable a gas exchange between the culture medium volume and the gas volume at the interface thereof.10-18-2012
20110003384COMPOSITIONS AND METHODS OF USE FOR MGD-CSF IN DISEASE TREATMENT - Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.01-06-2011
20120322150Mechanism and Method for Regulating Glycogen Synthase Kinase 3 (GSK3)-Related Kinases - The present invention relates to a novel mechanism for regulating GSK3 kinases, including BIN2 and human GSK3-beta, by dephosphorylating GSK3 kinases through the PP1 phosphatase, such as the plant BSU1 phosphatases and human PP1-gamma.12-20-2012
20120322151SMOOTH MUSCLE-LIKE CELLS (SMLCs) DERVIDED FROM HUMAN PLURIPOTENT STEM CELLS - This invention relates, e.g., to a method for differentiating mammalian (e.g., human) pluripotent stem cells (PSCs) into smooth muscle-like cells (SMLCs) in vitro, comprising a) plating a single-cell suspension of PSCs that are smaller than 50 μm at a seeding concentration of about 5×1012-20-2012
20120270315METHODS AND MEANS FOR OBTAINING MODIFIED PHENOTYPES - Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eukaryotic cells, particularly in plant cells, by providing aberrant, preferably unpolyadenylated, target-specific RNA to the nucleus of the host cell. Preferably, the unpolyadenylated target-specifc RNA is provided by transcription of a chimeric gene comprising a promoter, a DNA region encoding the target-specific RNA, a self-splicing ribozyme and a DNA region involved in 3′ end formation and polyadenylation.10-25-2012
20120270314NON-TUMORIGENIC EXPANSION OF PLURIPOTENT STEM CELLS - A method for expansion of human embryonic stem (hES) cells in a medium including human umbilical cord-derived mesenchymal stem cells (HUCMSCs) as a feeder is provided. The human embryonic stem cells (hES) maintain the features of embryonic stem cells in the medium, such as pluripotency, unlimited undifferentiated proliferation and normal karyotypes. Also provided is a method for non-tumorigenic expansion of the human embryonic stem cells (hES) that is free from forming teratoma.10-25-2012
20120094380HUMAN MULTIPOTENT EMBRYONIC STEM CELL-LIKE PROGENITOR CELLS - The invention provides a plurality of embryonic stem cell-like progenitor cells, which are isolated from a human tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells and a cell sorting by a cell antigen selected from the group consisting of CD34, CD117, CD133, CD201, GloboH and combination thereof, and cultured in a medium supplemented with at least one or more steroids and one or more growth factors. The cells of the invention express CD34 and exhibit sphere-like clonogenicity in early passages and express multipotent embryonic stem cells (ESCs) like characteristics.04-19-2012
20100203636Method for isolating islets of langerhans - Islets of Langerhans from a pancreas are isolated by exposing the pancreas to a very high-glucose (approximately 60 mM to 900 mM) solution to cause shrinking and accommodation of the acinar cells to the solution. Thereafter the very high-glucose solution is replaced with a low or zero-glucose solution to thereby selectively osmotically shock and swell acinar cells of the pancreas to destroy acinar tissue. If not previously minced during the initial exposure step, the treated pancreas is then minced, centrifuged and washed to thereby remove dead acinar cells and cell contents to leave islets of Langerhans. The islets are then placed in culture.08-12-2010
20100203635COMPOSITION AND METHOD FOR ENABLING PROLIFERATION OF PLURIPOTENT HUMAN STEM CELLS - Compositions and processes for culturing human stem cells in vitro in an undifferentiated state are disclosed. In this regard, human embryonic stem cells proliferated and maintained their pluripotency when cultured on plates coated with recombinant laminin-10 (laminin-511).08-12-2010
20100203634Inhibition of stem cell differentiation, enhancement of proliferation and selective induction of apoptosis by Wnt factors - The invention relates to a method for at least in part inhibiting differentiation of stem cells in a population of mammalian cells comprising up-regulating a Wnt-signaling pathway to a differentiation-inhibiting level in the population of cells. The invention increases at the same time the number of stem cells in a population of mammalian cells compared to a reference population, and induces, at least in part, apoptosis in mesenchymal cells in a population of mammalian cells. The invention also discloses a method for selective differentiation of a stem cell, comprising controlling the level of Wnt pathway activation. The invention is used for the proliferation and subsequent differentiation of embryonic stem cells and lung stem cells, and for ex vivo lung explant cultivation.08-12-2010
20110223661INHIBITORS OF STAT3 - Disclosed herein are compounds derived from a chemical structure according to the formula (I) wherein X comprises oxygen or sulfur, R09-15-2011
20110236972NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF - The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), capable of decreasing or silencing BIRC5 gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a BIRC5 mRNA. Also provided are methods of decreasing expression of a BIRC5 gene in a cell or in a subject to treat a BIRC5-related disease.09-29-2011
20100233807Substrate Recognition By Differentiable Human Mesenchymal Stem Cells - The invention described herein provides a structure for growing isolated differentiable human mesenchymal cells, which includes a three-dimensional matrix of fibers. The matrix serves as an implantable scaffolding for delivery of differentiable human mesenchymal cells in tissue engineering. The invention further provides compositions that contain the three-dimensional matrix of fibers seeded with isolated differentiable human mesenchymal cells, wherein the matrix forms a supporting scaffold for growing the isolated differentiable human mesenchymal cells, and wherein the differentiable human mesenchymal cells differentiate into a mature cell phenotype. The invention further provides methods of preparing the implantable nanofiber matrix scaffolding seeded with differentiable human mesenchymal cells for use in tissue engineering.09-16-2010
20120088301FACTOR TAKING PART IN TRANSCRIPTION CONTROL - HDART binds with HDAC (histone deacetylase) and function as a repressor. HDART directly binds with Skip functioning as a transcription co-activator of a nuclear receptor to repress the transcription of the nuclear receptor. Moreover, HDART is one of transcription co-repressors of nuclear receptor, and binds with HDAC thereby enabling intense repression of transcription through the histone deacetylization of HDAC. On the other hand, a dominant negative peptide of HDART can be obtained, and it has been confirmed that this peptide activates transcription contrary to the HDART protein of the full length. Especially, the transcription activity of retinoic acid receptor with this peptide has an activity exceeding all-trans retinoic acid (ATRA).04-12-2012
20120088300COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF DEFINITIVE ENDODERM - Certain embodiments disclosed herein are directed to a method of producing endoderm cells, such as definitive endoderm cells by exposing stem cells such as embryonic stem cells or induced pluripotent stem (iPS) cells to an effective amount of at least one compound described herein to differentiate the stem cells into the endoderm cells such as definitive endoderm cells. Differentated endoderm cells produced by the methods disclosed herein can be differentiated into pancreatic epithelium, and other endoderm derivatives such as thymus, liver, stomach, intestine and lung. Another aspect of the present invention relates to a method of producing pancreatic progenitor cells, such as Pdx1-positive pancreatic progenitor cells by exposing endoderm cells, such as definitive endoderm cells to an effective amount of at least one compound described herein to differentiate the definitive endoderm cells into Pdx1-positive pancreatic progenitor cells. Kits and compositions comprising Pdx1-positive pancreatic progenitor produced using the methods are also described.04-12-2012
20120329152INDUCTION, PROPAGATION AND ISOLATION OF LIVER PROGENITOR CELLS - The present invention relates to methods of induction and isolation of progenitor cells from stem cell cultures, specifically liver progenitor cells from human embryonic stem cell cultures. In one embodiment, the present invention provides a method of inducing hepatocyte-like progenitor cells by placing a quantity of human embryonic stem cells in a medium supplemented with an inhibitor of the MAPK/MEK/ERK signaling pathway, FGFR, GSK3 and/or BMP.12-27-2012
20120100607COMPOSITIONS OF ADULT DISC STEM CELLS AND METHODS FOR THE TREATMENT OF DEGENERATIVE DISC DISEASE - This invention provides a tissue growth apparatus comprising one or more discospheres and a method of producing nucleus pulposus cells comprising the step of growing one or more discospheres on the tissue growth apparatus. This invention also provides a neo-engineered disc comprising nucleus pulposus cells, and related methods of production and methods of use.04-26-2012
20100167397ENDOCRINE CELL LINES AND METHOD OF USING THE SAME - In accordance with the present invention, there are provided (1) various cell lines derived from hypothalamus and Langerhans islets of mammals, (2) process for producing an active peptide and expression cloning system of active peptide precursor gene using the cell line as a host, (3) a method of screening or evaluating a substance capable of acting on the cells using the cell line, (4) a method of screening or isolating a useful gene or useful peptide using the cell line and (5) a highly-sensitive and simple assay system for GPCR ligand used in the above expression cloning system.07-01-2010
20100167398METHOD OF CULTURING PLURIPOTENT STEM CELLS USING EXTRACELLULAR MATRIX FROM FETAL MEMBRANE-DERIVED CELLS - Provided are a method of culturing pluripotent stem cells in the presence of a decidua-derived cell or an extracellular matrix derived from the cell, that enables safe and efficient maintenance culture and derivation of pluripotent stem cells; a culture agent for pluripotent stem cells, that comprises a decidua-derived cell or an extracellular matrix derived from the cell; and other means for developing or performing the method.07-01-2010
20130011922NUCLEIC ACID COMPOUNDS FOR INHIBITING GENE EXPRESSION AND USES THEREOF - The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), and blunt ended double-stranded ribonucleic acid molecules capable of decreasing or silencing expression of a target gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target mRNA. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease or condition associated with the target gene.01-10-2013
20100129907HUMAN FORESKIN FIBROBLAST CONDITIONED MEDIA FOR CULTURING ES CELLS - A cell culture comprising human foreskin cells, the human foreskin cells being capable of maintaining stem cells in an undifferentiated state when co-cultured therewith.05-27-2010
20100129906Method for Obtaining Xeno-Free Hbs Cell line - A method for obtaining a stable xeno-free hBS cell line, xeno-free hBS cell lines obtained according to said method and use thereof. The method comprises the steps of: 05-27-2010
20130023049VIABLE CELLS FROM FROZEN UMBILICAL CORD TISSUE - Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.01-24-2013
20130023048Method of Inducing High Activity of Human Adipose Stem Cell and Medium Therefor - The present invention relates to a method of inducing high activity of human adipose stem cells, highly active stem cells induced by the method, cell therapeutic agents including the highly active stem cells, and a medium for inducing high activity of human adipose stem cells.01-24-2013
20080241920Method of promoting differentiation of one or more human stem cells into human coronary endothelial cells on a synthetic tubular structure - A method of promoting differentiation of one or more human stem cells into human coronary endothelial cells on at least one surface of a synthetic tubular structure to be used to make a human hybrid carotid graft is provided. The method includes arranging a plurality of human stem cells on the synthetic tubular structure to yield a hybrid stem cell/synthetic tubular structure and subjecting ex vivo, the hybrid stem cell/synthetic tubular structure to three dimensional dynamic conditions effective to promote differentiation of the one or more human stem cells into human coronary endothelial cells on the at least one surface.10-02-2008
20080311656Meiosis arrest in oocytes in vitro - The method for in vitro synchronisation of nuclear and cytoplasmatic maturation of GV oocytes from domestic animals or from primates can be improved if a phosphodiesterase type 3 inhibitor is added to the medium after collection of the oocytes and, thereafter, said phosphodiesterase type 3 inhibitor is removed to allow the nuclear maturation to proceed.12-18-2008
20110263016Expansion of Embryonic Stem Cells - The present invention addresses the problem of expanding human embryonic stem cell (hESC) and induced pluripotent stem cell (iPSC) populations to clinically relevant numbers while maintaining pluripotency. In particular, the use of macrolide antibiotics and inhibitors of Rho and Rho-associated kinases is described.10-27-2011
20130177980SYNTHETIC MATRICES FOR SELF-RENEWAL AND EXPANSION OF STEM CELLS - Provided herein is a synthetic polymer-based hydrogel for the self-renewal and expansion of human stem cells such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Also provided are methods of making and using the same.07-11-2013
20130177981METHOD OF MAKING BIOLOGICALLY ACTIVE ALPHA-BETA PEPTIDES - Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising α-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the α-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with β-amino acid residues, and the α-amino acid residues are distributed in a repeating pattern.07-11-2013
20130143317METHODS OF GROWING AN EMBRYO TO A BLASTOCYTE STAGE OF DEVELOPMENT - The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to a novel human embryo co-culture system to improve human embryo growth in vitro and, consequently, increase pregnancy rates in infertile women undergoing in vitro fertilization (IVF) treatment. More particularly, the present invention relates to a method of growing an embryo to a blastocyst stage of development comprising the step of coculturing said embryo in the presence of a population of cumulus cells.06-06-2013
20130115695SCALABLE PRIMATE PLURIPOTENT STEM CELL AGGREGATE SUSPENSION CULTURE AND DIFFERENTIATION THEREOF - The present invention relates to methods for production of undifferentiated or differentiated embryonic stem cell aggregate suspension cultures from undifferentiated or differentiated embryonic stem cell single cell suspensions and methods of differentiation thereof.05-09-2013
20130095566Flux Balance Analysis With Molecular Crowding - Methods are provided herein for: calculating cell growth rates in various environments and genetic backgrounds; calculating the order of substrate utilization from a defined growth medium; calculating metabolic flux reorganization in various environments and at various growth rates; and calculating the maximum metabolic rate and optimal metabolite concentrations and enzyme activities by applying a computational optimization method to a kinetic model of a metabolic pathway. The optimization methods use intracellular molecular crowding parameters and/or well as kinetic rates to assist in modeling metabolic activity.04-18-2013
20130095568MESODERM AND DEFINITIVE ENDODERM CELL POPULATIONS - The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy. The present invention further provides a method of generating hepatocytes, cell populations enriched for hepatocytes, and a method of hepatocyte replacement therapy.04-18-2013
20130130375USE OF FIBROBLAST GROWTH FACTOR FOR LINEAGE PRIMING AND DIFFERENTIATION OF PLURIPOTENT STEM CELLS - The present invention provides a method of inducing mesoderm derived cells from pluirpotent stem cells. In contrast to methods known in the art that are often designed to replicate in vivo events of mesoderm induction, the present invention provides a unique, yet simple, method whereby pluripotent stem cells are mesodermally primed in the presence of factors that concomitantly inhibit the spontaneous differentiation of endoderm and ectoderm during expansion and suspension steps. Exposure and/or adherence of primed aggregates to a extracellular matrix that promotes the commitment and survival of induced mesoderm progenitors, followed by exposure to various mesoderm associated factors, allows for the subsequent induction of such cells into terminally differentiated lineages, such as cardiomyocytes. End products of this induction system will ultimately provide an unlimited source of mesoderm-derived cell types for therapeutic and pharmacological purposes.05-23-2013
20110275151METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR - Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain.11-10-2011
20130149778Method and Applications of Peptide-Mediated Mitochondrial Delivery System - The present invention relates to a method using a cell penetrating peptide (Pep-1) for labeling and delivering mitochondria separated from healthy cells to replace damaged mitochondria. At present, microinjection of mitochondria into cells can only process one cell at a time, and therefore, this technique is limited to embryo related research and relevant applications. The advantages of the said peptide-mediated mitochondrial delivery system (PMD) include less steps with more efficiency, where a number of cells can be treated following one labeling process; the delivery process can be easily controlled, there is no cell toxicity after delivery under appropriate conditions, and delivery efficiency is over 80% depending on different cell types. Mitochondria delivered by the PMD system will move to the original mitochondrial location in the cells and will not be catalyzed in lysosomes; thus, the therapeutic effects can last at least one week.06-13-2013
20100317105Methods and compositions for controlling efficacy of RNA silencing - Based at least in part on an understanding of the mechanisms by which small RNAs (e.g., naturally-occurring miRNAs) mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, the effect of the position of the mismatches, etc. Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing.12-16-2010
20100317104CELL CULTURE MEDIA - A serum-free media composition for maintenance or directed differentiation of human embryonic stem cells (HESCs) toward particular cell lineages is disclosed. The media comprises one or more cell nutrient media, a recombinant human albumin or equivalent thereof and optionally at least one agent involved in HESC differentiation. The media composition is substantially free of any human or animal derived products.12-16-2010
20100317103EFFICIENT GENERATION OF NEURAL PROGENITORS, NEURONS, AND DOPAMINERGIC NEURONS FROM HUMAN EMBRYONIC STEM CELLS - The present invention relates to a method for inducing the differentiation of neural progenitors, neurons, and dopaminergic neurons from human embryonic stem cells with high efficiency, in which neural selection can be performed by the selected media and physical methods. The invention has advantages such as higher efficiency, the effect of lowering cost and time, and maintenance of neural progenitors for a longer period of time, as compared to the known methods for inducing the differentiation into neural progenitors, neurons, and dopaminergic neurons. Accordingly, the method can stably generate cells used for treating Parkinson's disease or other nervous system diseases.12-16-2010
20100317102Cell Culture Method and Automatic Culture System Using the Method - A culturing method according to the present invention including a step of injecting cells extracted from a human body and a culture medium into a culture container, (2) a step of culturing cells while performing air ventilation and exchange of the culture medium in the culture container in which the culture medium and the cells are put, (3) a step of cleaning cultured cells which are cultured in the culture container and then withdrawing the cleaned cells from the culture container into a cell withdrawing vessel while some of the cleaned cells are left in the culture container, (4) a step of injecting a culture medium to the cultured cells left in the culture container in the step (3), and (5) a step of repetitively executing the step (2,) and the step (3).12-16-2010
20130157358Method for neuroepithelial cells differentiation from pluripotent stem cells and medium using same - The present invention discloses a neural induction medium comprising Wnt-signal agonist, TGFβ-signal inhibitor and FGF-signal agonist for inducing neural differentiation. The neural induction medium used in a culture system is capable for inducing the neural differentiation of stem cells into neuroepithelial cells which are useful for the clinical applications. Therein, the neuroepithelial cells can further differentiate into mature neurons for the practical applications including regeneration medicine and drug discovery for neural disorders.06-20-2013
20130157359FGF HAVING ENHANCED STABILITY - Methods are provided that exploit thermostable FGF-1 proteins for support of human pluripotent stem cell cultures. Also provided are compositions containing thermostable FGF-1 for culturing of human pluripotent stem cells.06-20-2013
20130157360BIOMIMETIC TISSUE SCAFFOLD AND METHODS OF MAKING AND USING SAME - Three-dimensional biomimetic tissue scaffolds, as well as methods of manufacture of these scaffolds. The method is fully customizable to create a biomimetic tissue scaffold with shapes, densities, and geometries similar or identical to the tissue it imitates. For example, physiologically realistic collagen/PEG villi created using the method are designed to have a high-aspect ratio and curvature similar to villi found in the human small intestine. Accordingly, the biomimetic tissue scaffolds serve as an improved in vitro model for a wide variety of physiological research, as well as pharmacological testing and drug, compound, and/or metabolite uptake by cells growing on the scaffold, among many other uses.06-20-2013
20120282692Oocytes Derived from Ovarian Culture Initially Containing No Oocytes - Ovarian germ-line-competent embryonic stem cells (GLC-ESC) are cultured, either in the presence or absence of a compound having estrogenic activity. The GLC-ESC are either collected prior to specific commitment or are permitted to remain in the culture medium for a time sufficient to develop into oocytes, and the oocytes may be fertilized by adding sperm to the culture medium. The fertilized oocytes may be permitted to develop into embryos, which may be transferred into the uterus of an adult human female or frozen for later use. The invention provides a method for obtaining by in vitro fertilization an embryo that is genetically related to a human female who is not producing oocytes.11-08-2012
20120282690ATMOSPHERE CONTROL COMPOSITION - The atmosphere control composition according to the present invention is an atmosphere control composition for use in the culture of cells, which comprises (a) an ascorbic acid component, (b) water, (c) a porous carrier, (d) an aldehyde-removing agent, (e) a transition metal catalyst and/or an alkaline earth metal hydroxide, wherein the aldehyde-removing agent comprises at least one component selected from the group consisting of ethylene urea, urea, arginine, lysine hydrochloride and a polyallylamine. According to the present invention, the atmosphere control composition feasible for preventing the generation of aldehyde can be provided without affecting the oxygen absorption ability and the carbon dioxide generation ability thereof.11-08-2012
20130122588Compositions Comprising Human Embryonic Stem Cells and Their Derivatives, Methods of Use, and Methods of Preparation - The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells.05-16-2013
20130122587METHOD FOR DIFFERENTIATING CARTILAGE CELLS, BONE CELLS, NERVE CELLS OR FAT CELLS FROM HUMAN INFERIOR TURBINATE MESENCHYMAL STROMAL CELLS - There is provided a method for differentiating human turbinate mesenchymal stromal cells into bone cells, cartilage cells, nerve cells, or fat cells, in which the method includes a step of culturing the mesenchymal stromal cells that are isolated from human inferior turbinate tissues in a medium containing growth factors; and also to a composition for preventing or treating cartilage injuries or diseases, bone injuries or metabolic bone diseases, or nerve injuries or diseases, in which the composition includes cells differentiated by the method as active ingredients. The bone cells, cartilage cells, nerve cells. or fat cells can be used in the fields of cell replacement therapy and regenerative medicine for treating diseases caused by the damage of the cells, and the human inferior turbinate tissues can be easily obtained as the source of the cells from the discarded tissues during inferior turbinate surgery.05-16-2013
20110312089PROCESS FOR CULTIVATING CELLS - A process for cultivation of differentiated human cells retaining stem cell potential is provided. The process comprises culturing differentiated human cells retaining stem cell potential anchored to a microcarrier selected from the group consisting of gelatin microcarriers and quaternary ammonium derivatised polystyrene microcarriers.12-22-2011
20130189777Differentiation of Human Embryonic Stem Cells into Single Hormonal Insulin Positive Cells - The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.07-25-2013
20120021513SMALL MOLECULES SUPPORTING PLURIPOTENT CELL GROWTH AND METHODS THEREOF - The present invention relates to compositions and methods for maintaining undifferentiated pluripotent stem cell cultures.01-26-2012
20120021512Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.01-26-2012
20120028352Microcarriers for Stem Cell Culture - We disclose a particle comprising a matrix coated thereon and having a positive charge, the particle being of a size to allow aggregation of primate or human stem cells attached thereto. The particle may comprise a substantially elongate, cylindrical or rod shaped particle having a longest dimension of between 50 μm and 400 μm, such as about 200 μm. It may have a cross sectional dimension of between 20 μm and 30 μm. The particle may comprise a substantially compact or spherical shaped particle having a size of between about 20 μm and about 120 μm, for example about 65 μm. We also disclose a method of propagating primate or human stem cells, the method comprising: providing first and second primate or human stem cells attached to first and second respective particles, allowing the first primate or human stem cell to contact the second primate or human stem cell to form an aggregate of cells and culturing the aggregate to propagate the primate or human stem cells for at least one passage. A method of propagating human embryonic stem cells (hESCs) in long term suspension culture using microcarriers coated in Matrigel or hyaluronic acid is also disclosed. We also disclose a method for differentiating stem cells.02-02-2012
20130196431TISSUE ENGINEERED BLOOD VESSEL - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed.08-01-2013
20100015706NUCLEIC ACID COMPOUNDS FOR INHIBITING HIF1A GENE EXPRESSION AND USES THEREOF - The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing HIF1A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a HIF1A mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a HIF1A gene in a cell or in a subject to treat a HIF1A-related disease.01-21-2010
20130203166STIMULATION OF MULTIPOTENCY OF MESENCHYMAL STEM CELLS BY CHEMOKINE CCL5 - Methods of stimulating multipotency, proliferation and differentiation of isolated mesenchymal stem cells (MSCs), which permit more effective differentiation and integration of such cells into host tissues. The method includes providing an in vitro cell population of MSCs and administering CCL5 chemokine. Preferably CCL is administered in an amount sufficient to induce expression of one or more multipotency related genes selected from the group consisting of OCT3/4, NANOG, SOX 2, KLF4, and SOX9.08-08-2013
20090191626Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells - Synthetic surfaces suitable for culturing stem cell derived oligodendrocyte progenitor cells contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived oligodendrocyte progenitor cells in chemically defined media.07-30-2009
20130203165SWELLABLE (METH)ACRYLATE SURFACES FOR CULTURING CELLS IN CHEMICALLY DEFINED MEDIA - Synthetic surfaces capable of supporting culture of undifferentiated human embryonic stem cells in a chemically defined medium include a swellable (meth)acrylate layer and a peptide conjugated to the swellable (meth)acrylate layer. The swellable (meth)acrylate layer may be formed by polymerizing monomers in a composition that includes hydroxyethyl methacrylate, 2-carboxyehylacrylate, and tetra(ethylene glycol)dimethacrylate. The conjugated peptide may include an amino acid sequence of Xaa08-08-2013
20120077269USE OF A PROTEIN IN STEM CELL AND CANCER APPLICATIONS - The present invention discloses a novel antibody HES5:3:3 directed towards a specific antigen present on human pluripotent stem (hPS) cells and cancer tissue. The antibody can be used as a tool for human pluripotent stem (hPS) cell applications, such as the separation, surface adhesion and enhanced survival of said hPS cells. Furthermore, the present invention refers to the use of the antigen detection for cancer applications.03-29-2012
20130095567DIRECTED DIFFERENTIATION AND MATURATION OF PLURIPOTENT CELLS INTO HEPATOCYTE LIKE CELLS BY MODULATION OF WNT-SIGNALLING PATHWAY - Provided are improved methods using Glycogen synthase kinase 3 (GSK3) inhibitors by which endodermal cells, notably endodermal cells derived from human pluripotent stem cells (hPS), such as but not limited to hiPS-cells and hES-cells may be differentiated into hepatocyte like cells. The specific modulation of wingless integration gene (WNT)-signalling pathway and use of GSK3 inhibitors achieve direct differentiation and maturation of hepatocytes derived from human pluripotent stem (hPS) cells. GSK-3 inhibitors, when added to the growth medium at certain developmental stages, leads to more mature and functional features for the hepatocyte like cells as well as more pure and homogenous populations of hepatocyte like cells. Provided are also hepatocyte like cells obtained by these methods as well as compositions comprising them.04-18-2013
20120094379HUMAN ENDOMETRIOSIS CELL - The present invention discloses a human endometriosis cell, EM 257, which has been stored in the food industry research and development institute. Results obtained from a flow cytometry reveal that the human endometriosis cell of the present invention is positive for the mesnchymal stem cell surface antigens, such as CD44, CD73, CD105 and CD146. In different differentiation conditions, the human endometriosis cell of the present invention can be differentiated into osteogenic or adipogenic lineage cells.04-19-2012
20130210138SOMATIC CELL REPROGRAMMING - The present invention relates to methods for reprogramming a somatic cell to pluripotency by administering into the somatic cell at least one or a plurality of potency-determining factors. The invention also relates to pluripotent cell populations obtained using a reprogramming method.08-15-2013
20130210140CELL CARRIERS AND METHODS FOR CULTURING CELLS - A carrier for growing stem cells is provided, the carrier comprises a substrate comprising one or more outer surfaces; and a hydrophilic, water soluble coating material disposed and dried on one or more of the outer surfaces. The carrier comprises one or more structured indentations on one or more of the outer surfaces, wherein the carrier has a length at least about 0.2 mm, a width at least about 0.2 mm, and a height in a range from about 0.05 mm to 1.2 mm and each of the structured indentations has a major axis in a range from about 0.1 mm to 0.5 mm, a minor axis in a range from about 0.1 mm to 0.5 mm and a depth in a range from about 0.025 mm to about 0.5 mm. A method of culturing stem cells and stromal cells using the same carrier are also provided.08-15-2013

Patent applications in class Human

Patent applications in all subclasses Human